<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Open Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Open Biol</journal-id>
<journal-id journal-id-type="publisher-id">RSOB</journal-id>
<journal-id journal-id-type="hwp">royopenbio</journal-id>
<journal-title-group>
<journal-title>Open Biology</journal-title>
</journal-title-group>
<issn pub-type="epub">2046-2441</issn>
<publisher>
<publisher-name>The Royal Society</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30991935</article-id>
<article-id pub-id-type="pmc">6501648</article-id>
<article-id pub-id-type="doi">10.1098/rsob.190041</article-id>
<article-id pub-id-type="publisher-id">rsob190041</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>15</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
<subj-group subj-group-type="leader">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>ADP-ribosylation signalling and human disease</article-title>
<alt-title alt-title-type="short">ADP-ribosylation signalling and disease</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-5556-5549</contrib-id>
<name>
<surname>Palazzo</surname>
<given-names>Luca</given-names>
</name>
<xref ref-type="aff" rid="af1">1</xref>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mikolčević</surname>
<given-names>Petra</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mikoč</surname>
<given-names>Andreja</given-names>
</name>
<xref ref-type="aff" rid="af2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-9446-3756</contrib-id>
<name>
<surname>Ahel</surname>
<given-names>Ivan</given-names>
</name>
<xref ref-type="aff" rid="af3">3</xref>
<xref ref-type="corresp" rid="cor2"></xref>
</contrib>
</contrib-group>
<aff id="af1"><label>1</label><institution>Institute of Protein Biochemistry, National Research Council</institution>, <addr-line>Via Pietro Castellino 111, 80131 Naples</addr-line>, <country>Italy</country></aff>
<aff id="af2"><label>2</label><institution>Division of Molecular Biology, Ruđer Bošković Institute</institution>, <addr-line>Bijenička cesta 54, 10000 Zagreb</addr-line>, <country>Croatia</country></aff>
<aff id="af3"><label>3</label><institution>Sir William Dunn School of Pathology, University of Oxford</institution>, <addr-line>South Parks Road, OX1 3RE Oxford</addr-line>, <country>UK</country></aff>
<author-notes>
<corresp id="cor1">e-mail: <email>l.palazzo@ibp.cnr.it</email></corresp>
<corresp id="cor2">e-mail: <email>ivan.ahel@path.ox.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>17</day>
<month>4</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>9</volume>
<issue>4</issue>
<elocation-id>190041</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>3</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 The Authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>Published by the Royal Society under the terms of the Creative Commons Attribution License <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>, which permits unrestricted use, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="rsob-9-190041.pdf"></self-uri>
<self-uri xlink:href="rsob190041.thumb.gif" xlink:role="icon"></self-uri>
<self-uri content-type="reviewer_comments" xlink:href="rsob190041_review_history.pdf"></self-uri>
<abstract>
<p>ADP-ribosylation (ADPr) is a reversible post-translational modification of proteins, which controls major cellular and biological processes, including DNA damage repair, cell proliferation and differentiation, metabolism, stress and immune responses. In order to maintain the cellular homeostasis, diverse ADP-ribosyl transferases and hydrolases are involved in the fine-tuning of ADPr systems. The control of ADPr network is vital, and dysregulation of enzymes involved in the regulation of ADPr signalling has been linked to a number of inherited and acquired human diseases, such as several neurological disorders and in cancer. Conversely, the therapeutic manipulation of ADPr has been shown to ameliorate several disorders in both human and animal models. These include cardiovascular, inflammatory, autoimmune and neurological disorders. Herein, we summarize the recent findings in the field of ADPr, which support the impact of this modification in human pathophysiology and highlight the curative potential of targeting ADPr for translational and molecular medicine.</p>
</abstract>
<kwd-group>
<kwd>ADP-ribosylation</kwd>
<kwd>signalling</kwd>
<kwd>translational medicine</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Cancer Research UK</institution>
<institution-id>http://dx.doi.org/10.13039/501100000289</institution-id>
</institution-wrap>
</funding-source>
<award-id>C35050/A22284</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Hrvatska Zaklada za Znanost</institution>
<institution-id>http://dx.doi.org/10.13039/501100004488</institution-id>
</institution-wrap>
</funding-source>
<award-id>IP-2016-06-4242</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Fondazione Italiana per la Ricerca sul Cancro</institution>
<institution-id>http://dx.doi.org/10.13039/501100007076</institution-id>
</institution-wrap>
</funding-source>
<award-id>14895</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Wellcome Trust</institution>
<institution-id>http://dx.doi.org/10.13039/100004440</institution-id>
</institution-wrap>
</funding-source>
<award-id>101794</award-id>
<award-id>210634</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>April 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1">
<label>1.</label>
<title>Introduction</title>
<p>Uni- and multicellular organisms rely on multiple dynamic molecular processes dictating cellular growth, cell division, prompt adaptation to environmental changes and survival. A functional and dynamic communication between cellular macromolecules is essential to control these fundamental biological processes. At the molecular level, proteins and small molecules are responsible for orchestrating these cellular responses. Cells have evolved mechanisms able to regulate dynamically proteins' functions through chemical modifications. In this regard, post-translational modifications (PTMs) can efficiently and very rapidly control a multitude of cellular processes in a time-dependent fashion by affecting the conformation, activity, stability, interactions and the sequestration of proteins to cellular compartments and organelles [<xref ref-type="bibr" rid="RSOB190041C1">1</xref>].</p>
<p>So far, more than 300 PTMs have been described; each one is involved in a range of fundamental cellular and biological processes. Functional alterations in the proteins governing PTM systems are frequently dysregulated in human disease [<xref ref-type="bibr" rid="RSOB190041C1">1</xref>].</p>
<p>Among the PTMs, there is ADP-ribosylation (ADPr). ADPr is the transfer of a single or multiple ADP-ribose unit(s) from nicotinamide adenine dinucleotide (NAD<sup>+</sup>) onto target protein substrates. Importantly, ADP-ribose nucleotide units can be also transferred onto nucleic acids and small molecules, such as on acetyl chemical groups to produce <italic>O</italic>-acetyl-ADP-ribose (OADPR) during de-acetylation reactions [<xref ref-type="bibr" rid="RSOB190041C2">2</xref>–<xref ref-type="bibr" rid="RSOB190041C4">4</xref>].</p>
<p>Although ADPr of proteins was first described in the early 1960s, our understanding of the cellular processes regulated by ADPr is still in its infancy [<xref ref-type="bibr" rid="RSOB190041C5">5</xref>–<xref ref-type="bibr" rid="RSOB190041C8">8</xref>]. Indeed, strikingly little is known about most of the proteins involved in ADPr and the governed signalling pathways. Such a gap in the knowledge also translates into a lack of understanding of many potentially related pathogenic mechanisms. Yet the therapeutic modulation of ADPr is emerging as a strategy with high potential in the clinic of certain human cancer types [<xref ref-type="bibr" rid="RSOB190041C9">9</xref>,<xref ref-type="bibr" rid="RSOB190041C10">10</xref>].</p>
<p>However, an in-depth understanding of molecular networks controlled by ADPr can not only further potentiate current clinical strategies, but also impact on the treatment of many other human diseases with no available therapy identified so far. Herein we discuss the most recent discoveries available in the scientific community supporting the central role of ADPr in the pathophysiology of many acquired and hereditary human diseases (summarized in <xref ref-type="table" rid="RSOB190041TB1">table 1</xref>) and highlight the outcomes of the pharmacological modulation of ADPr for the clinical treatment of these disorders.
<table-wrap id="RSOB190041TB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Alterations of ADPr genes associated with human inherited pathologies.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" colspan="1" rowspan="1">gene</th><th align="left" colspan="1" rowspan="1">gene alteration</th><th align="left" colspan="1" rowspan="1">disease/disorder</th><th align="left" colspan="1" rowspan="1">references</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">transferases</td></tr><tr><td colspan="1" rowspan="2">PARP9</td><td colspan="1" rowspan="2">overexpression</td><td colspan="1" rowspan="1">B-aggressive lymphoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C11">11</xref>,<xref ref-type="bibr" rid="RSOB190041C12">12</xref>]</td></tr><tr><td colspan="1" rowspan="1">breast cancer</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C13">13</xref>]</td></tr><tr><td colspan="1" rowspan="4">PARP14</td><td colspan="1" rowspan="4">overexpression</td><td colspan="1" rowspan="1">B-aggressive lymphoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C11">11</xref>,<xref ref-type="bibr" rid="RSOB190041C14">14</xref>]</td></tr><tr><td colspan="1" rowspan="1">sarcoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C15">15</xref>]</td></tr><tr><td colspan="1" rowspan="1">asthma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C16">16</xref>]</td></tr><tr><td colspan="1" rowspan="1">hepatocellular carcinoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C17">17</xref>]</td></tr><tr><td colspan="1" rowspan="1">PARP15</td><td colspan="1" rowspan="1">overexpression</td><td colspan="1" rowspan="1">B-aggressive lymphoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C11">11</xref>]</td></tr><tr><td colspan="4" rowspan="1">readers/erasers</td></tr><tr><td colspan="1" rowspan="3">ALC1 (CHD1L)</td><td colspan="1" rowspan="3">overexpression</td><td colspan="1" rowspan="1">hepatocellular carcinoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C18">18</xref>]</td></tr><tr><td colspan="1" rowspan="1">breast cancer</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C19">19</xref>]</td></tr><tr><td colspan="1" rowspan="1">colorectal carcinoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C20">20</xref>]</td></tr><tr><td colspan="1" rowspan="1">ARH1</td><td colspan="1" rowspan="1">missense mutations</td><td colspan="1" rowspan="1">lung, breast and colon cancers</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C21">21</xref>]</td></tr><tr><td colspan="1" rowspan="1">ARH3</td><td colspan="1" rowspan="1">truncations/mutations</td><td colspan="1" rowspan="1">neurodegenerative diseases</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C22">22</xref>,<xref ref-type="bibr" rid="RSOB190041C23">23</xref>]</td></tr><tr><td colspan="1" rowspan="1">GDAP2 (MacroD3)</td><td colspan="1" rowspan="1">point mutations</td><td colspan="1" rowspan="1">ataxia, progressive spasticity and dementia</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C24">24</xref>]</td></tr><tr><td colspan="1" rowspan="4">MacroD1</td><td colspan="1" rowspan="4">overexpression</td><td colspan="1" rowspan="1">endometrial carcinoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C25">25</xref>]</td></tr><tr><td colspan="1" rowspan="1">gastric carcinoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C26">26</xref>]</td></tr><tr><td colspan="1" rowspan="1">colorectal carcinoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C27">27</xref>,<xref ref-type="bibr" rid="RSOB190041C28">28</xref>]</td></tr><tr><td colspan="1" rowspan="1">breast carcinoma</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C29">29</xref>,<xref ref-type="bibr" rid="RSOB190041C30">30</xref>]</td></tr><tr><td colspan="1" rowspan="4">MacroD2</td><td colspan="1" rowspan="1">single-nucleotide polymorphisms</td><td colspan="1" rowspan="1">autism</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C31">31</xref>–<xref ref-type="bibr" rid="RSOB190041C33">33</xref>]</td></tr><tr><td colspan="1" rowspan="1">microdeletion Int 5</td><td colspan="1" rowspan="1">kabuki syndrome</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C34">34</xref>,<xref ref-type="bibr" rid="RSOB190041C35">35</xref>]</td></tr><tr><td colspan="1" rowspan="1">locus deletions</td><td colspan="1" rowspan="1">various cancers</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C36">36</xref>,<xref ref-type="bibr" rid="RSOB190041C37">37</xref>]</td></tr><tr><td colspan="1" rowspan="1">deletions, missense mutations</td><td colspan="1" rowspan="1">colorectal cancer</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C38">38</xref>]</td></tr><tr><td colspan="1" rowspan="1">TARG1</td><td colspan="1" rowspan="1">premature stop codon</td><td colspan="1" rowspan="1">neurodegeneration</td><td colspan="1" rowspan="1">[<xref ref-type="bibr" rid="RSOB190041C39">39</xref>]</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="s2">
<label>2.</label>
<title>ADP-ribosyl transferases</title>
<p>ADPr is carried out by transferase enzymes that, based on the homology of their catalytic domain with bacterial toxins, are classified in two enzyme superfamilies: the cholera toxin-like ADP-ribosyl transferases (ARTCs) and the diphtheria toxin-like ADP-ribosyl transferases (ARTDs) [<xref ref-type="bibr" rid="RSOB190041C2">2</xref>,<xref ref-type="bibr" rid="RSOB190041C40">40</xref>,<xref ref-type="bibr" rid="RSOB190041C41">41</xref>]. These two classes of enzymes share an evolutionarily conserved protein fold, called ADP-ribosyl transferase (ART) domain [<xref ref-type="bibr" rid="RSOB190041C40">40</xref>,<xref ref-type="bibr" rid="RSOB190041C41">41</xref>]. The ART protein fold is characterized by two central β-sheets, one anti-parallel sheet containing three to five β strands, and one sheet composed of four to five β strands [<xref ref-type="bibr" rid="RSOB190041C40">40</xref>–<xref ref-type="bibr" rid="RSOB190041C42">42</xref>].</p>
<p>Three crucial amino acids within the ART domain define the affiliation to cholera or diphtheria toxin-like superfamilies, the R-S-E and H-Y-E triads, respectively. The first two amino acids in the triad are important for the NAD<sup>+</sup> binding, while the common glutamate functions in catalysis [<xref ref-type="bibr" rid="RSOB190041C40">40</xref>–<xref ref-type="bibr" rid="RSOB190041C42">42</xref>]. ARTCs and ARTDs also differ for their specificity to target distinct amino acids. Most of the characterized ARTCs target protein substrates on arginine residues in proteins through an <italic>N</italic>-glycosidic bond producing arginine-ADPr (Arg-ADPr; <xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). The founding member of ARTC family is the cholera toxin from <italic>Vibrio cholerae</italic>. Cholera toxin modifies arginine 187 of the stimulatory Gs<italic>α</italic> subunit of heterotrimeric G protein. ADPr of Gs<italic>α</italic> leads to constitutive activation of cyclic AMP-signalling pathway and, in turn, a dramatic efflux of ions and water from infected enterocytes, leading to watery diarrhoea [<xref ref-type="bibr" rid="RSOB190041C43">43</xref>,<xref ref-type="bibr" rid="RSOB190041C44">44</xref>].
<fig id="RSOB190041F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Enzymes and mechanisms of protein ADP-ribosylation. NAD, nicotinamide adenine dinucleotide; Na, nicotinamide; ADPr, ADP-ribose.</p></caption><graphic xlink:href="rsob-9-190041-g1"></graphic></fig>
</p>
<p>ARTD group of transferases most commonly modify acidic groups [<xref ref-type="bibr" rid="RSOB190041C45">45</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). The founding member of ARTD family is the diphtheria toxin, an exotoxin secreted by <italic>Corynebacterium diphtheriae</italic>, which catalyses the modification of the eukaryotic elongation factor-2 (EF-2) at a modified amino acid called diphthamide, thus inhibiting the translation machinery of the host [<xref ref-type="bibr" rid="RSOB190041C44">44</xref>,<xref ref-type="bibr" rid="RSOB190041C46">46</xref>]. For further details about bacterial ADP-ribosyl transferase toxins (bARTTs), refer to §9.</p>
<p>Four members of ARTC superfamily are expressed in humans (ARTC1, ARTC3, ARTC4, and ARTC5) and six in mice (Artc1, Artc2.1, Artc2.2, Artc3, Artc4 and Artc5). ARTC1, ARTC2, ARTC3 and ARTC4 enzymes are bound to the cellular plasma membrane by a glycosyl-phosphatidyl-inositol (GPI) anchor, while ARTC5 is an extracellular secreted enzyme. ARTC1, ARTC2 and ARTC5 show mono-ADP-ribosyl transferase activity and modify arginine side chains of protein substrates (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). On the contrary, ARTC3 and ARTC4 lack the R-S-E motif in the active centre and therefore are probably inactive enzymes [<xref ref-type="bibr" rid="RSOB190041C47">47</xref>,<xref ref-type="bibr" rid="RSOB190041C48">48</xref>].</p>
<p>Mainly, extracellular or plasma membrane-residing proteins are substrates of Arg-ADPr, such as P2X7 and haemopexin [<xref ref-type="bibr" rid="RSOB190041C47">47</xref>,<xref ref-type="bibr" rid="RSOB190041C48">48</xref>]. However, several studies revealed Arg-ADPr of intracellular proteins as well (e.g. BIP, GAPDH and tubulin) [<xref ref-type="bibr" rid="RSOB190041C49">49</xref>–<xref ref-type="bibr" rid="RSOB190041C52">52</xref>], though the ARTs responsible for intracellular Arg-ADPr remain largely unknown.</p>
<p>Seventeen members of the ARTD superfamily have been identified in mammals and are known as poly(ADP-ribose) polymerases (PARPs) [<xref ref-type="bibr" rid="RSOB190041C3">3</xref>,<xref ref-type="bibr" rid="RSOB190041C41">41</xref>,<xref ref-type="bibr" rid="RSOB190041C53">53</xref>]. PARPs most commonly transfer ADP-ribose onto aspartic/glutamic acids (Asp/Glu-ADPr), through ester linkages, and on serine (Ser-ADPr) residues through <italic>O</italic>-glycosylation [<xref ref-type="bibr" rid="RSOB190041C54">54</xref>,<xref ref-type="bibr" rid="RSOB190041C55">55</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). Several PARPs can produce chains of ADP-ribose polymers (also called poly(ADP-ribose), thus abbreviated as PAR), where repeating single ADP-ribose units (up to 200 in length) are linked via unique <italic>O</italic>-glycosidic ribose-ribose bonds [<xref ref-type="bibr" rid="RSOB190041C45">45</xref>,<xref ref-type="bibr" rid="RSOB190041C56">56</xref>–<xref ref-type="bibr" rid="RSOB190041C58">58</xref>]. This type of modification is generally named poly(ADP-ribosyl)ation (PARylation). Well-characterized PARPs able to generate PARylation are PARP1, PARP2, Tankyrase-1 and Tankyrase-2 [<xref ref-type="bibr" rid="RSOB190041C45">45</xref>]. However, the remaining human PARP members are instead only capable of transferring a single ADP-ribose group to their target proteins, thus producing mono(ADP-ribosyl)ation (also abbreviated as MARylation) [<xref ref-type="bibr" rid="RSOB190041C45">45</xref>,<xref ref-type="bibr" rid="RSOB190041C59">59</xref>,<xref ref-type="bibr" rid="RSOB190041C60">60</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>).</p>
</sec>
<sec id="s3">
<label>3.</label>
<title>ADP-ribosyl hydrolases</title>
<p>ADPr is a fully reversible PTM. Two unrelated protein families show hydrolytic activity against proteins modified by ADPr, with diverse target specificity; the ADP-ribosyl-acceptor hydrolases (ARHs) and the macrodomain-containing enzymes.</p>
<p>Mg<sup>2+</sup>-dependent ADP-ribosyl-acceptor hydrolases (ARHs) are classified as DraG-like fold-containing proteins, based on the homology encountered with the bacterial dinitrogenase reductase-activating glycohydrolase (DraG). Bacterial DraG homologues have been described as mono(ADP-ribosyl) hydrolases that control nitrogen fixation by counteracting the arginine modifying ART activity of DraT [<xref ref-type="bibr" rid="RSOB190041C61">61</xref>]. Three ARH members are found in mammals: ARH1 (also named ADPRH), ARH2 (also named ADPRHL1) and ARH3 (also named ADPRHL2). While an enzymatic activity has not been identified for ARH2, ARH1 and ARH3 have distinct substrate specificities [<xref ref-type="bibr" rid="RSOB190041C62">62</xref>–<xref ref-type="bibr" rid="RSOB190041C64">64</xref>]. As seen for the bacterial DraG proteins, ARH1 reverses Arg-ADPr synthesized by both mammal endogenous ARTCs and bacterial toxins [<xref ref-type="bibr" rid="RSOB190041C64">64</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). Indeed, <italic>Arh1</italic>-deficient mice show enhanced sensitivity to cholera toxin infection [<xref ref-type="bibr" rid="RSOB190041C65">65</xref>]. By contrast, ARH3 shows high activity on <italic>O</italic>-glycosidic bonds and is the only known enzyme possessing hydrolytic activity against Ser-ADPr [<xref ref-type="bibr" rid="RSOB190041C66">66</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). Interestingly, ARH3 is inhibited by the metabolite ADP-ribosyl arginine, suggesting a cross talk between ADPr systems [<xref ref-type="bibr" rid="RSOB190041C67">67</xref>].</p>
<p>Macrodomain-containing proteins share a common ADP-ribose recognition domain, which is called macrodomain. The macrodomain is an ADP-ribose binding unit that plays crucial roles in the sensing and hydrolysis of ADPr in different cellular contexts [<xref ref-type="bibr" rid="RSOB190041C68">68</xref>]. Macrodomains are found in vertebrates as well as in many bacteria, archaea, viruses and plants, suggesting their evolutionary conservation and wide utility [<xref ref-type="bibr" rid="RSOB190041C69">69</xref>]. Depending on the type, macrodomains can exhibit the ability to bind ADP-ribose or PAR or OADPR (a metabolite released from the sirtuin-mediated NAD<sup>+</sup>-dependent deacetylation reaction). In addition, some macrodomains also act as ADP-ribosyl hydrolases [<xref ref-type="bibr" rid="RSOB190041C42">42</xref>,<xref ref-type="bibr" rid="RSOB190041C68">68</xref>–<xref ref-type="bibr" rid="RSOB190041C71">71</xref>]. Nevertheless, several macrodomain-containing proteins have been suggested to bind RNA intermediates instead of ADP-ribose [<xref ref-type="bibr" rid="RSOB190041C69">69</xref>,<xref ref-type="bibr" rid="RSOB190041C72">72</xref>].</p>
<p>Among the 12 macrodomain-containing proteins encoded by the human genome, only four exhibit catalytic activity [<xref ref-type="bibr" rid="RSOB190041C2">2</xref>,<xref ref-type="bibr" rid="RSOB190041C3">3</xref>,<xref ref-type="bibr" rid="RSOB190041C68">68</xref>,<xref ref-type="bibr" rid="RSOB190041C69">69</xref>]. The poly(ADP-ribosyl)glycohydrolase (PARG) is the only macrodomain-containing protein that efficiently cleaves PAR chains, though, it is unable to remove the terminal ADP-ribose linked to protein substrates [<xref ref-type="bibr" rid="RSOB190041C73">73</xref>]. Conversely, MacroD1 and MacroD2 of the MacroD subfamily of proteins as well as Terminal ADP-ribose glycosylhydrolase 1 (TARG1/C6orf130 or OARD1) specifically hydrolyse protein MARylation on acidic residues [<xref ref-type="bibr" rid="RSOB190041C39">39</xref>,<xref ref-type="bibr" rid="RSOB190041C74">74</xref>,<xref ref-type="bibr" rid="RSOB190041C75">75</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>).</p>
</sec>
<sec id="s4">
<label>4.</label>
<title>PARP1</title>
<p>PARP1 is the best-studied PARP enzyme, which is also the most ubiquitous and abundant PARP protein [<xref ref-type="bibr" rid="RSOB190041C57">57</xref>]. Together with PARP2 and PARP3, PARP1 belongs to the DNA-dependent nuclear PARPs group whose catalytic activity is potently stimulated by DNA breaks [<xref ref-type="bibr" rid="RSOB190041C10">10</xref>,<xref ref-type="bibr" rid="RSOB190041C76">76</xref>,<xref ref-type="bibr" rid="RSOB190041C77">77</xref>]. However, over the years, PARP1 functions have been expanded with roles in DNA damage repair as well as transcription, chromatin structure and metabolism [<xref ref-type="bibr" rid="RSOB190041C76">76</xref>,<xref ref-type="bibr" rid="RSOB190041C78">78</xref>–<xref ref-type="bibr" rid="RSOB190041C80">80</xref>]. Thus, PARP1 appears to be involved in both basal processes and response to cellular stresses with implications in human disease, particularly in cancer. For instance, PARP1 functions in DNA damage repair are the most attractive strategy to induce selective cell death in DNA damage repair-deficient cancers. Novel and specific structure-based chemicals acting as inhibitors of DNA damage PARPs (most notably PARP1) have been developed and under experimentation for treatment of pathological conditions [<xref ref-type="bibr" rid="RSOB190041C9">9</xref>,<xref ref-type="bibr" rid="RSOB190041C10">10</xref>,<xref ref-type="bibr" rid="RSOB190041C81">81</xref>,<xref ref-type="bibr" rid="RSOB190041C82">82</xref>]. The topic of PARP1 inhibitors in cancer will not be discussed in detail in this review.</p>
<p>The regulation of PARP1 activity is essential. A distinct PARP1 interacting protein milieu may play a crucial role in the fine-tuning of PARP1 when it functions in specific physiological processes or stress conditions. One of the best-characterized PARP1 accessory proteins is Histone PARylation Factor 1 (HPF1), which is required during the switch from basal conditions to stress response [<xref ref-type="bibr" rid="RSOB190041C83">83</xref>]. HPF1 has a central role in triggering PARP1-dependent ADPr of histone proteins as well as of many other DNA damage-related proteins following genotoxic stresses [<xref ref-type="bibr" rid="RSOB190041C83">83</xref>,<xref ref-type="bibr" rid="RSOB190041C84">84</xref>]. In the presence of DNA damage, HPF1 directs PARP1 to modify target proteins on serine residues within conserved motifs usually preceded by lysine residues (KS motifs) [<xref ref-type="bibr" rid="RSOB190041C54">54</xref>,<xref ref-type="bibr" rid="RSOB190041C84">84</xref>,<xref ref-type="bibr" rid="RSOB190041C85">85</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). Notably, most of the DNA damage-inducible ADPr is lost in the absence of HPF1. Importantly, PARP1 can still modify itself and other proteins on acidic residues in both DNA-damaged and undamaged cells in the absence of HPF1 [<xref ref-type="bibr" rid="RSOB190041C85">85</xref>].</p>
<p>In addition to the modification of DNA repair proteins, PARP1/HPF1-dependent Ser-ADPr targets include many other proteins involved in the maintenance of the genome stability. Indeed, in response to oxidative DNA damage, Ser-ADPr has been found linked to RNA processing, chromatin modification, splicing, transcription factors and mitotic proteins [<xref ref-type="bibr" rid="RSOB190041C84">84</xref>,<xref ref-type="bibr" rid="RSOB190041C86">86</xref>,<xref ref-type="bibr" rid="RSOB190041C87">87</xref>]. Interestingly, Ser-ADPr often overlaps with phosphorylation sites on proteins; such as Ser-ADPr of Ser10 on Histone H3, a well-known mitotic marker [<xref ref-type="bibr" rid="RSOB190041C54">54</xref>,<xref ref-type="bibr" rid="RSOB190041C85">85</xref>,<xref ref-type="bibr" rid="RSOB190041C88">88</xref>]. Proteome-wide studies have further expanded this observation, showing that Ser-ADPr occupies serine phosphorylation sites of many proteins that are also target of the mitotic regulators Aurora A and Aurora B kinases [<xref ref-type="bibr" rid="RSOB190041C86">86</xref>]. In addition, Ser-ADPr has been shown to compete with other PTMs by steric hindrance, in particular with modifications targeting the histone tails [<xref ref-type="bibr" rid="RSOB190041C88">88</xref>,<xref ref-type="bibr" rid="RSOB190041C89">89</xref>].</p>
<sec id="s4a">
<label>4.1.</label>
<title>Role of PARP1 in human diseases</title>
<p>Although <italic>PARP1</italic> genetic alterations are not associated with any known inherited disease, PARP1 is involved in the pathogenesis of many human disorders. For instance, depletion of NAD<sup>+</sup> induced by PARP1 over-activation as well as excessive synthesis of PAR associates with ischaemia reperfusion injury, myocardial infarction and neurodegenerative disorders [<xref ref-type="bibr" rid="RSOB190041C90">90</xref>–<xref ref-type="bibr" rid="RSOB190041C94">94</xref>]. These disorders as well as many other acute or chronic pathological processes share a common pathogenic mechanism, which involves the production of reactive oxygen (ROS) or nitrogen species (NOS) followed by DNA damage and PARP1 activation. For instance, PARP1 was found activated in myocardial sections of patients with circulatory shock, with a degree of PARP activation correlating with the degree of myocardial dysfunction. Similar observations were made in circulating leucocytes in patients affected by myocardial infarction and therapeutic revascularization [<xref ref-type="bibr" rid="RSOB190041C95">95</xref>–<xref ref-type="bibr" rid="RSOB190041C97">97</xref>]. Moreover, PARP1 activation was shown in brain specimens of patients who died of stroke or brain ischaemia attributable to cardiac arrest, as well as in patients affected by brain trauma [<xref ref-type="bibr" rid="RSOB190041C98">98</xref>,<xref ref-type="bibr" rid="RSOB190041C99">99</xref>]. Finally, there is evidence for a boost of PARylation mediated by PARP1 in autoimmune (e.g. systemic lupus erythematosus) and inflammatory diseases (e.g. colitis), as well as in human atherosclerotic plaques, microvessels and lymphocytes of type 2 diabetic patients [<xref ref-type="bibr" rid="RSOB190041C100">100</xref>–<xref ref-type="bibr" rid="RSOB190041C108">108</xref>].</p>
<p>This body of information suggests a central role for PARP1 in human disorders. Indeed, the chemical modulation of PARP1 can be proposed to ameliorate or treat many pathological conditions, from cardiovascular, inflammatory and autoimmune diseases to neurological disorders. We next describe the role of PARP1 activation and the effects of its inhibition in the pathogenesis of neurological disorders, such as in a rare cerebellar ataxia caused by biallelic loss of function mutations of XRCC1, Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) [<xref ref-type="bibr" rid="RSOB190041C94">94</xref>,<xref ref-type="bibr" rid="RSOB190041C109">109</xref>,<xref ref-type="bibr" rid="RSOB190041C110">110</xref>].</p>
</sec>
<sec id="s4b">
<label>4.2.</label>
<title>PARP1 in neurological disorders</title>
<p>The base excision repair (BER) X-ray repair cross-complementing 1 (XRCC1) protein is a molecular scaffold protein that is recruited by PAR and PARP1 on DNA damage foci. The BRCT domain of XRCC1 mediates its recruitment on DNA damage sites, and it is vital for the assembly of DNA single-strand break repair (SSBR) protein factors [<xref ref-type="bibr" rid="RSOB190041C111">111</xref>–<xref ref-type="bibr" rid="RSOB190041C115">115</xref>]. Importantly, several DNA-end processing enzymes recruited by XRCC1 are mutated in human ataxias, such as the spinocerebellar ataxia with axonal neuropathy-1 (SCAN1; mutated in TDP1), ataxia oculomotor apraxia-1 (AOA1; mutated in aprataxin) and ataxia oculomotor apraxia-4 (AOA4; mutated in PNKP) [<xref ref-type="bibr" rid="RSOB190041C116">116</xref>–<xref ref-type="bibr" rid="RSOB190041C121">121</xref>]. Furthermore, compound heterozygous mutations in human <italic>XRCC1</italic> gene were shown to be responsible for ocular motor apraxia, axonal neuropathy and progressive cerebellar ataxia [<xref ref-type="bibr" rid="RSOB190041C109">109</xref>]. Mechanistically, in the presence of DNA damage, XRCC1 depletion results in severe delays in DNA SSBR repair and hyper-recombination phenotypes, which are accompanied by PARP1 hyper-activation followed by elevated levels of nuclear ADPr. The hyper-recombination as well as the cerebellar ataxia phenotype in <italic>Xrcc1</italic> knockout mice is rescued by <italic>Parp1</italic> gene deletion but not by enzymatic inhibition of PARP1. Thus, preventing the binding of PARP1 to DNA but not its enzymatic inhibition can be exploited for the therapeutic treatment of clinical cerebellar ataxias associated with unrepaired SSBs [<xref ref-type="bibr" rid="RSOB190041C109">109</xref>].</p>
<p>The genetic or enzymatic modulation of PARP1 has been also proposed for other common neurodegenerative diseases, such as PD, ALS and AD. These neurological disorders have a common pathogenic mechanism, which is characterized by aggregation of cytotoxic proteins, elevated levels of oxidative stress followed by DNA damage, PARP1 activation and excess of cellular levels of PAR.</p>
<p>In PD, intracellular monomeric α-synuclein assembles into higher-ordered protein aggregates that can spread from cell to cell [<xref ref-type="bibr" rid="RSOB190041C122">122</xref>]. Aggregates of α-synuclein activate nitric oxide synthase followed by production of NOS, which in turn cause DNA damage and activation of PARP1, and nuclear production of PAR. In a pathogenic loop, PAR is transported into the cytosol where it binds α-synuclein and further accelerates fibrillization and misfolding of the cytotoxic protein. Accumulation of pathologic α-synuclein ultimately leads to cell death via parthanatos and neuronal dysfunction. Inhibition of PARP activity or <italic>Parp1</italic> gene deletion fully mitigates neuron-to-neuron transmission of pathologic α-synuclein and neurotoxicity; thus, PARP inhibitors (PARPi) can be exploited as therapeutic intervention for PD [<xref ref-type="bibr" rid="RSOB190041C110">110</xref>].</p>
<p>The liaison between protein aggregations, ROS formation, DNA damage and PARP1 activation has been also largely shown in AD. A peptide of 39–42 amino acids (Aβ) is the major component of protein aggregates present in AD senile plaques. Aβ is produced by the sequential proteolytic processing of the amyloid precursor protein (APP) by β- and γ-secretases [<xref ref-type="bibr" rid="RSOB190041C123">123</xref>]. Genetic and/or environmental factors are responsible for an imbalance between production and clearance of A β, which in turn leads to Aβ oligomerization and production of higher-order soluble assemblies and protofibrils and fibrils [<xref ref-type="bibr" rid="RSOB190041C123">123</xref>]. Through the impairment of the mitochondrial electron transport and the interaction with metal ions (Cu<sup>2+</sup>, Zn<sup>2+</sup> and Fe<sup>2+</sup>), the aggregation of Aβ leads to ROS production and PARP1 activation [<xref ref-type="bibr" rid="RSOB190041C124">124</xref>–<xref ref-type="bibr" rid="RSOB190041C131">131</xref>]. The chemical inhibition of PARP1 blocks the accumulation of PAR and the morphological transformation in microglia-induced Aβ [<xref ref-type="bibr" rid="RSOB190041C130">130</xref>].</p>
<p>In ALS, the normally nuclear RNA/DNA-binding protein TDP-43 redistributes in the cytoplasm of affected neurons and glial cells, and forms phosphorylated protein aggregates [<xref ref-type="bibr" rid="RSOB190041C132">132</xref>,<xref ref-type="bibr" rid="RSOB190041C133">133</xref>]. TDP-43 and other proteins mutated in ALS (e.g. Ataxin-2) are a component of stress granules (SGs). SGs are cytoplasmic membraneless structures composed of RNAs and associated proteins structures, which form well cellular-defined zones of stalled translation complexes in response to a variety of environmental stresses that interfere with mRNA translation [<xref ref-type="bibr" rid="RSOB190041C134">134</xref>,<xref ref-type="bibr" rid="RSOB190041C135">135</xref>]. Among the cellular stresses inducing SGs there are heat shock, glucose deprivation, oxidative stress and viral infection [<xref ref-type="bibr" rid="RSOB190041C136">136</xref>,<xref ref-type="bibr" rid="RSOB190041C137">137</xref>]. Importantly, several PARPs and PAR itself have been shown to localize and regulate SGs formation; for instance, PARP1, Tankyrase-1 (also known as PARP5a), PARP12, the two PARP13 splice variants (PARP13.1 and PARP13.2) and PARP15 [<xref ref-type="bibr" rid="RSOB190041C138">138</xref>–<xref ref-type="bibr" rid="RSOB190041C142">142</xref>]. In ALS, motor neurons in the spinal cord show high levels of nuclear staining of PAR, suggesting massive PARP1 activation. In turn, PARP1 activity facilitates the nuclear export and the cytoplasmic aggregation of TDP-43 by an unknown mechanism. Indeed, the specific inhibition of PARP1 by Veliparib mitigates the formation of stress-induced aggregates of TDP-43 in the cytoplasm [<xref ref-type="bibr" rid="RSOB190041C141">141</xref>]. Altogether, these data suggest that PARP1 plays a central role in the formation of stress granules and, therefore, in the pathogenesis of TDP-43-dependent ALS [<xref ref-type="bibr" rid="RSOB190041C140">140</xref>,<xref ref-type="bibr" rid="RSOB190041C141">141</xref>]. Interestingly, other PARPs have a clear role in the pathophysiology of TDP-43-associated ALS in addition to PARP1; <italic>Drosophila melanogaster</italic> Tankyrase-1 and Tankyrase-2 (also known as PARP-5a and PARP-5b; refer to §6 for details) regulate the specific cytoplasmic aggregation of TDP-43. Importantly, contrary to PARP1, the inhibition of tankyrases does not alter the overall formation of SGs [<xref ref-type="bibr" rid="RSOB190041C142">142</xref>]. Thus, the differential impact of PARPs' inhibition on formation of SGs suggests that PARP1 is deputed to the overall control of SG formation, while tankyrase activity is specifically required for TDP-43 nuclear-SG translocation. Through a PAR-binding motif in its N-terminal nuclear localization sequence, TDP-43 non-covalently binds PAR. The binding of TDP-43 to PAR leads to liquid–liquid phase separation of protein, which is required for its accumulation in stress granules. Downregulation of tankyrases and inhibition of PARP catalytic activity by using small-molecules reduces the accumulation of TDP-43 in the cytoplasm and potently mitigates neurodegeneration [<xref ref-type="bibr" rid="RSOB190041C142">142</xref>].</p>
<p>Altogether, all studies summarized above uncover a common role for PAR in the regulation of the subcellular re-distribution of proteins in response to cellular stresses and, eventually, in their cytosolic aggregation. Thus, the inhibition of PARPs’ functions can be considered a therapeutic strategy for neurological disorders that are characterized by PAR-dependent protein aggregation. Inhibitors of PARP1 activity possessing significant brain penetration are already commercially available, such as Pamiparib (BeiGene/Merck Serono) [<xref ref-type="bibr" rid="RSOB190041C10">10</xref>]. Nevertheless, new drugs may be required to specifically treat certain disorders that show different pathogenic mechanisms (e.g. XRCC1-dependent ataxias) [<xref ref-type="bibr" rid="RSOB190041C109">109</xref>].</p>
</sec>
<sec id="s4c">
<label>4.3.</label>
<title>PARP1 in inflammation-induced colorectal cancer</title>
<p>It is worth mentioning the contribution of PARP1 as well as of other ADPr players (see §§7 and 8) to the pathogenesis of inflammatory bowel disease. Colitis refers to inflammation of the inner lining of the colon. There are numerous causes of colitis including infection, ischaemia and allergic reactions. The inflammatory bowel diseases, Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory disorders of the gastrointestinal tract of unknown aetiology. The diseases are thought to be the result of a dysregulated mucosal immune response to commensal gut flora in genetically susceptible individuals [<xref ref-type="bibr" rid="RSOB190041C143">143</xref>–<xref ref-type="bibr" rid="RSOB190041C147">147</xref>]. Importantly, the association between long-standing and extensive colitis and an increased risk of colorectal cancer (CRC) is well established [<xref ref-type="bibr" rid="RSOB190041C148">148</xref>–<xref ref-type="bibr" rid="RSOB190041C150">150</xref>].</p>
<p>PARP1 plays crucial roles in both colon inflammation and CRC. By using protocols of carcinogenesis in animal models, it has been shown that PARP1 is required to protect against DNA alkylation and oxidation damage during the initial steps of CRC carcinogenesis. Consistent with this, PARP1-deficient mice challenged with alkylating drugs show high levels of DNA strand breaks compared with control animals, thus, confirming that PARP1 works as a caretaker tumour suppressor gene [<xref ref-type="bibr" rid="RSOB190041C151">151</xref>]. In addition, PARP1 promotes tumour growth by supporting the focal inflammation during the tumour progression. Indeed, PARP1-deficient mice show an attenuated innate immune response. The pro-inflammatory functions of PARP1 pass through the modulation of NF-κB activity and following activation of the IL6-STAT3-Cyclin D1 axis. Importantly, tissue microarray analyses reveal that <italic>PARP1</italic> is overexpressed in human CRC and its expression levels correlate with disease progression [<xref ref-type="bibr" rid="RSOB190041C151">151</xref>].</p>
</sec>
</sec>
<sec id="s5">
<label>5.</label>
<title>Macrodomain-containing PARPs in human disease</title>
<p>Twelve macrodomain-containing proteins are encoded in the human genome, including the previously mentioned hydrolase enzymes [<xref ref-type="bibr" rid="RSOB190041C3">3</xref>,<xref ref-type="bibr" rid="RSOB190041C42">42</xref>,<xref ref-type="bibr" rid="RSOB190041C68">68</xref>,<xref ref-type="bibr" rid="RSOB190041C69">69</xref>]. Three understudied PARP members are equipped with a number of macrodomains in addition to the PARP catalytic protein fold; thus, they are named Macro-PARPs [<xref ref-type="bibr" rid="RSOB190041C3">3</xref>,<xref ref-type="bibr" rid="RSOB190041C11">11</xref>,<xref ref-type="bibr" rid="RSOB190041C68">68</xref>]. Macro-PARPs were originally identified as members of a B-aggressive lymphoma protein family, which includes PARP9 (B-aggressive lymphoma 1; BAL1, also called ARTD9), PARP14 (BAL2, also called ARTD8) and PARP15 (BAL3, also called ARTD7) [<xref ref-type="bibr" rid="RSOB190041C11">11</xref>].</p>
<p><italic>PARP9</italic> (<italic>BAL1</italic>) was identified in a genome-wide search for risk-related genes in chemo-resistant diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma. <italic>PARP9</italic> is largely overexpressed in DLBCL and promotes cell migration [<xref ref-type="bibr" rid="RSOB190041C11">11</xref>,<xref ref-type="bibr" rid="RSOB190041C12">12</xref>]. <italic>PARP9</italic> is also overexpressed in breast cancer [<xref ref-type="bibr" rid="RSOB190041C13">13</xref>]. At the molecular level, PARP9 plays roles in DNA damage repair. In response to DNA damaging agents, PARP9 localizes at the DNA damage foci via its macrodomain, which drives PARP9 at the PARP1-generated PAR foci. There, PARP9 interacts with the E3 ligase DTX3L (also known as B lymphoma- and BAL-associated protein; BBAP) and promotes DNA damage repair via the ubiquitination-dependent recruitment of BRCA1 (Breast Cancer Type 1 susceptibility protein), 53BP1 (p53-binding protein 1) and RAP80 (receptor-associated protein 80) [<xref ref-type="bibr" rid="RSOB190041C152">152</xref>]. PARP9 activity negatively regulates the function of PARP9/DTX3 L heterodimer complex by transferring single units of ADP-ribose specifically on the carboxyl terminal of glycine 76 of ubiquitin molecules, thus interfering with the canonical protein ubiquitylation system [<xref ref-type="bibr" rid="RSOB190041C153">153</xref>]. The oncogenic potential of PARP9 has been described to be dependent on its transcriptional functions, particularly required for IFNγ-mediated host inflammatory response. PARP9, whose expression is activated by IFNγ, interacts with the IFNγ receptor complex and STAT1 acting as a transcriptional co-repressor of anti-proliferative and pro-apoptotic genes, and as a co-activator for the transcription of responsive proto-oncogenes, such as IRF2 and B-cell CLL/lymphoma 6 (BCL6) [<xref ref-type="bibr" rid="RSOB190041C154">154</xref>,<xref ref-type="bibr" rid="RSOB190041C155">155</xref>].</p>
<p>PARP14 (BAL2) was initially identified as an interactor and transcriptional collaborator for Signal Transducer and Activator of Transcription 6 (STAT6) and, therefore, named Co-activator of STAT6 (CoaSt6) [<xref ref-type="bibr" rid="RSOB190041C156">156</xref>]. PARP14 plays roles mainly in transcription of interleukin-4 (IL4)-responsive genes, which control cell survival, metabolism and proliferation [<xref ref-type="bibr" rid="RSOB190041C14">14</xref>]. Under non-stimulating conditions, PARP14 binds the transcriptional repressors histone deacetylase 2 (HDAC2) and HDAC3 at IL4-responsive promoters [<xref ref-type="bibr" rid="RSOB190041C16">16</xref>]. Under IL4 stimulation, PARP14 ADP-ribosylates HDAC 2 and 3 leading to their dissociation and the recruitment of transcriptional co-activators including the p100 cofactor, which is also a substrate of PARP14 [<xref ref-type="bibr" rid="RSOB190041C16">16</xref>,<xref ref-type="bibr" rid="RSOB190041C157">157</xref>]. This process leads to the transcription of IL4-responsive genes, which are vital for both B and T cells. In B cells, PARP14-dependent transcription of IL4-responsive genes transduces pro-survival and anti-apoptotic signals [<xref ref-type="bibr" rid="RSOB190041C14">14</xref>]. In addition, by regulating the binding of STAT6 to the <italic>Gata3</italic> promoter, PARP14 and its enzyme activity are required for differentiation of T cells towards a T helper type-2 (Th2) lineage [<xref ref-type="bibr" rid="RSOB190041C158">158</xref>]. Th2 cells and Th2 cytokines (e.g. IL4, 5 and 13) associate with the promotion of IgE and eosinophilic responses and play a central role in the response to allergens, therefore, Th2 are the initiators of the allergic asthmatic condition [<xref ref-type="bibr" rid="RSOB190041C159">159</xref>]. Inhibition of PARP14 attenuates allergic airway disease, and it has been proposed as therapeutic strategy for asthma [<xref ref-type="bibr" rid="RSOB190041C158">158</xref>].</p>
<p>In addition to the transcriptional functions, PARP14 plays crucial roles in the metabolic control of cancer cells. PARP14 is indeed involved in the control of the cytokine-regulated glycolysis and glucose oxidation, thus, aiding the B-lymphoid oncogenesis [<xref ref-type="bibr" rid="RSOB190041C160">160</xref>]. Studies on solid tumours, such as sarcoma and hepatocarcinoma, further corroborate the link between PARP14 and cellular metabolism. In sarcoma cancer cells, PARP14 was shown to stabilize the glycolytic enzymes phosphoglucose isomerase (PGI) [<xref ref-type="bibr" rid="RSOB190041C15">15</xref>]. When secreted into the extracellular environment, PGI acts as a cytokine eliciting motogenic and differentiation cellular responses and, in addition, facilitates angiogenesis, metastasis and vessel leakiness [<xref ref-type="bibr" rid="RSOB190041C161">161</xref>–<xref ref-type="bibr" rid="RSOB190041C163">163</xref>]. In hepatocellular carcinoma, PARP14 inhibits JNK1-dependent phosphorylation and activation of the pyruvate kinase M2 isoform (PKM2), thus, promoting the aerobic glycolysis (Warburg effect) of cancer cells [<xref ref-type="bibr" rid="RSOB190041C17">17</xref>].</p>
<p>Lastly, PARP14 is involved in PARP10-dependent intracellular signalling. PARP14 binds MARylated proteins with high-affinity through its macrodomains. Among the ADPr proteins, PARP14 binds very efficiently automodified PARP10 and MARylated substrates of PARP10, such as the small GTPase RAN and the component of the NF-κB signal transduction pathway NEMO [<xref ref-type="bibr" rid="RSOB190041C164">164</xref>].</p>
</sec>
<sec id="s6">
<label>6.</label>
<title>Role of tankyrases in the pathogenesis of cherubism</title>
<p>Tankyrase-1 and Tankyrase-2 are PARP enzymes characterized by large ankyrin repeating domains. Tankyrases play roles in telomere length maintenance which is particularly relevant for ageing, homologous recombination-mediated DNA damage response, mitosis, pexophagy, and Wnt- and Notch-mediated signal transduction [<xref ref-type="bibr" rid="RSOB190041C165">165</xref>–<xref ref-type="bibr" rid="RSOB190041C174">174</xref>].</p>
<p>Differently from other PARPs, tankyrases engage their protein substrates through the ankyrin domains within their protein sequence that bind very efficiently a well-defined octapeptide consensus within protein substrates [<xref ref-type="bibr" rid="RSOB190041C175">175</xref>]. The consensus for binding to tankyrase proteins consists of arginine in position 1, small and hydrophobic residue in position 4, aspartate in position 5, however, glutamic acid, valine, glutamine, tyrosine, isoleucine and cysteine are equally tolerated, and glycine in position 6 [<xref ref-type="bibr" rid="RSOB190041C175">175</xref>]. Protein–protein interaction is therefore the prerequisite for tankyrase-dependent PARylation. A large number of binders/substrates of tankyrase proteins have been proposed by interaction studies (608 proteins) [<xref ref-type="bibr" rid="RSOB190041C173">173</xref>,<xref ref-type="bibr" rid="RSOB190041C175">175</xref>]. Among tankyrase-interacting proteins there are AXIN1/2, the telomeric-repeat binding factor-1 (TRF1), the insulin-responsive amino-peptidase (IRAP), the 182-kDa tankyrase-binding protein (TAB182), the nuclear mitotic apparatus protein-1 (NuMA1), 3BP2, Notch2, HectD1, NKD1 and NKD2, the CBP80/CBP20-dependent translation initiation factor (CTIF), BLZF1 (basic leucine zipper factor 1), CASC3 (cancer susceptibility factor 3), the component of the HIPPO signalling pathways AMOT (Angiomotin) and PTEN, although it is not clear whether the latter is a direct tankyrase-binding protein or substrate [<xref ref-type="bibr" rid="RSOB190041C165">165</xref>,<xref ref-type="bibr" rid="RSOB190041C168">168</xref>,<xref ref-type="bibr" rid="RSOB190041C170">170</xref>,<xref ref-type="bibr" rid="RSOB190041C173">173</xref>,<xref ref-type="bibr" rid="RSOB190041C176">176</xref>–<xref ref-type="bibr" rid="RSOB190041C180">180</xref>]. Following the interaction and PARylation, a large portion of tankyrase-binding proteins become targets of proteasome degradation [<xref ref-type="bibr" rid="RSOB190041C175">175</xref>]. Indeed, tankyrase-mediated PARylation of protein substrates acts as a scaffold for recruitment of the PAR binding motif-containing protein RNF146, an E3 ubiquitin ligase. Thus, RNF146 binds tankyrases' PARylated substrates and ubiquitinates them, leading to their proteasome degradation. The liaison between tankyrase-mediated ADPr and proteasome degradation was initially observed in the regulation of the proliferative WNT pathway in CRC cells through the modification and following degradation of AXIN1/2, then expanded to many other cellular processes regulated by tankyrase substrates [<xref ref-type="bibr" rid="RSOB190041C10">10</xref>,<xref ref-type="bibr" rid="RSOB190041C170">170</xref>,<xref ref-type="bibr" rid="RSOB190041C181">181</xref>]. Thereby, the interest in targeting tankyrase proteins for the pharmacological modulation of pathological conditions has increased in recent times. In particular, the involvement of tankyrases in Wnt signalling (related to tumourigenesis) and glucose homeostasis (related to diabetes) promises advances for targeting tankyrases for therapeutic interventions, as demonstrated by the pre-clinical experimentation of tankyrase inhibitors for treatment of CRC [<xref ref-type="bibr" rid="RSOB190041C10">10</xref>,<xref ref-type="bibr" rid="RSOB190041C170">170</xref>,<xref ref-type="bibr" rid="RSOB190041C181">181</xref>–<xref ref-type="bibr" rid="RSOB190041C186">186</xref>]. In addition, the chemical inhibition of tankyrase proteins has been proposed for treatment of brain injuries of the newborn. Indeed, tankyrase small inhibitors stabilize Axin2 levels in oligodendrocyte progenitor cells from brain and spinal cord, thus accelerating differentiation and myelination after hypoxic and demyelinating injury [<xref ref-type="bibr" rid="RSOB190041C187">187</xref>].</p>
<p>Dysregulation of tankyrase-mediated binding and degradation of protein substrates has been recognized as the pathogenic mechanism of cherubism, a dominantly inherited human disorder. Cherubism is a bone inflammatory destructive disease characterized by deformities of the facial bones [<xref ref-type="bibr" rid="RSOB190041C188">188</xref>]. Cherubism is caused by single missense mutations in Sh3bp2, the gene that encodes the adaptor protein 3BP2 [<xref ref-type="bibr" rid="RSOB190041C189">189</xref>]. Most 3BP2 mutations associated with cherubism cluster within the peptide sequence RSPPDG, such as R413Q, P416H, or G418R mutations, which serve as a tankyrase-interacting motif. Similar to all known targets of tankyrase, PARylation of 3BP2 leads to its proteasome degradation, which is required for controlling 3BP2 protein levels within the cells. In cherubism, 3BP2 mutations in the RSPPDG hexapeptide impair tankyrase-mediated protein degradation, which in turn translates into elevated steady-state protein levels of 3BP2 in primary cells deputed to maintain the bone homeostasis, namely osteoclasts. As a result of this dysregulation, the signalling pathway including SRC, SYK and VAV proteins is up-regulated leading to uncontrolled activation of osteoclasts’ functions and peculiar interosseous fibrocystic lesions in cherubism-affected patients [<xref ref-type="bibr" rid="RSOB190041C175">175</xref>,<xref ref-type="bibr" rid="RSOB190041C190">190</xref>].</p>
</sec>
<sec id="s7">
<label>7.</label>
<title>Role of ADP-ribosyl hydrolases in human disease</title>
<sec id="s7a">
<label>7.1.</label>
<title>Macrod1 and MacroD2</title>
<p>MacroD1 and MacroD2 are related mono(ADP-ribosyl) hydrolases belonging to a subfamily of proteins present in both eukaryotes and prokaryotes [<xref ref-type="bibr" rid="RSOB190041C191">191</xref>]. MacroD1 and D2 contain nearly identical catalytic macrodomains that, by using substrate-assisted catalysis, hydrolyse the ester bond joining the ADP-ribose to the acidic residues of acceptor proteins or cleaving OADPR [<xref ref-type="bibr" rid="RSOB190041C74">74</xref>,<xref ref-type="bibr" rid="RSOB190041C192">192</xref>]. However, MacroD1 and D2 cannot hydrolyse the <italic>O</italic>-glycosidic bond of Ser-ADPr [<xref ref-type="bibr" rid="RSOB190041C66">66</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>).</p>
<p>MacroD1 (also named Leukaemia-Related Protein 16; LRP16) contains a leading sequence localizing the protein at the mitochondria; nevertheless, its roles in transcription as a cofactor for androgen and oestrogen receptors and in NF-κB signal transduction cascade have been largely established [<xref ref-type="bibr" rid="RSOB190041C193">193</xref>–<xref ref-type="bibr" rid="RSOB190041C196">196</xref>].</p>
<p>MacroD1 appears overexpressed in several human cancers (such as endometrial carcinoma, gastric carcinoma, CRC and breast carcinoma) and its expression levels correlate with poor prognostic outcomes [<xref ref-type="bibr" rid="RSOB190041C25">25</xref>–<xref ref-type="bibr" rid="RSOB190041C30">30</xref>]. It is worth mentioning that the oncogenic potential of MacroD1 in CRC depends on its ability to activate the pro-survival NF-κB-dependent signalling in the presence of DNA damage. When stimulated by DNA-damaging agents, MacroD1 enriches in the cytosol of CRC cells where it interacts with double-stranded RNA-dependent kinase (PKR), thus facilitating the kinase activation, and promoting the binding with IKKβ. The formation of MacroD1/PKR/IKKβ ternary complex triggers the activation of anti-apoptotic signals mediated by NF-κB. Importantly, a screening of molecules targeting MacroD1 macrodomain led to the identification of a small molecule (MRS2578) that, both <italic>in vitro</italic> and <italic>in vivo</italic>, abrogates MacroD1- and NF-κB-dependent pro-survival signals synergistically with DNA-damaging chemotherapies [<xref ref-type="bibr" rid="RSOB190041C28">28</xref>].</p>
<p>The other member of the MacroD subfamily, MacroD2, also shows connections with the NF-κB pathway. MacroD2 was shown to play a central role in reverting PARP10-dependent MARylation of protein substrates, as in the case of GSK3<italic>β</italic> kinase, a kinase involved in the WNT pathway. Additionally, MacroD2 may revert PARP10-dependent MARylation of NEMO (NF-κB essential modulator), modification of which results in reduced NEMO polyubiquitylation and decreased NF-κB signalling [<xref ref-type="bibr" rid="RSOB190041C68">68</xref>,<xref ref-type="bibr" rid="RSOB190041C75">75</xref>,<xref ref-type="bibr" rid="RSOB190041C197">197</xref>,<xref ref-type="bibr" rid="RSOB190041C198">198</xref>].</p>
<p>In disease, MacroD2 shows association with neurological disorders, such as autism and kabuki syndrome (KS), as well as cancer.</p>
<p>Autism is a heterogeneous neurodevelopmental disorder defined by deficits in language and social behaviour, as well as patterns of repetitive behaviours of high heritability [<xref ref-type="bibr" rid="RSOB190041C199">199</xref>,<xref ref-type="bibr" rid="RSOB190041C200">200</xref>]. However, a simpler genetic basis for autistic or autistic-like traits is recognizable in around 5% of autism individuals with diseases [<xref ref-type="bibr" rid="RSOB190041C201">201</xref>]. Single-nucleotide polymorphisms (SNPs) associated with autism are found in few candidate genes, among them the <italic>MacroD2</italic> gene [<xref ref-type="bibr" rid="RSOB190041C31">31</xref>–<xref ref-type="bibr" rid="RSOB190041C33">33</xref>]. kabuki (or Niikawa-Kuroki) syndrome is a genetically heterogeneous dominant mental retardation with a described autosomal transmission. It is characterized by postnatal growth retardation, typical facial defects, fetal pads, cleft palate and major malformations of the heart, kidneys and vertebra [<xref ref-type="bibr" rid="RSOB190041C202">202</xref>]. A mutation screening revealed a 250 kilobase <italic>de novo</italic> microdeletion at 20p12.1, which hits intron 5 of <italic>MACROD2</italic> gene and associates in one patient with kabuki syndrome [<xref ref-type="bibr" rid="RSOB190041C34">34</xref>]. An intron 5 deletion of the <italic>MACROD2</italic> gene was also reported in a patient displaying a kabuki-like phenotype [<xref ref-type="bibr" rid="RSOB190041C35">35</xref>]. It is worth mentioning that the association between an intron deletion of <italic>MACROD2</italic> gene and kabuki syndrome is reported in a small number of clinical cases. Thus, more research is needed to clarify the specific link between <italic>MACROD2</italic> and KS [<xref ref-type="bibr" rid="RSOB190041C203">203</xref>]. Genome-wide DNA copy-number analyses across human cancers have indeed revealed that common focal deletions of <italic>MACROD2</italic> genomic locus happen in multiple malignancies, such as in stomach adenocarcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, esophageal carcinoma, uterine corpus endometrial carcinoma, uterine carcinosarcoma, lung adenocarcinoma, liver hepatocellular carcinoma and thyroid carcinoma [<xref ref-type="bibr" rid="RSOB190041C36">36</xref>,<xref ref-type="bibr" rid="RSOB190041C37">37</xref>]. Importantly, some <italic>MACROD2</italic> somatic mutations are found in CRC. Loss of variable size of the genomic locus containing <italic>MACROD2</italic> as well as missense mutations is quite frequent in CRC. Importantly, some <italic>MACROD2</italic> somatic mutations observed in cancer are predicted to interfere with binding of ADP-ribose to the catalytic pocket of MacroD2, therefore leading to increased sensitivity to genotoxic stress, and chromosomal instability in CRC [<xref ref-type="bibr" rid="RSOB190041C38">38</xref>].</p>
</sec>
<sec id="s7b">
<label>7.2.</label>
<title>Terminal ADP-ribose glycosylhydrolase 1 (TARG1)</title>
<p>TARG1 (c6orf130) is a macrodomain-containing protein with similar substrate specificities as seen for MacroD1 and MacroD2—it can cleave glutamate-linked protein ADPr, OADPR and phosphate-linked ADPr on nucleic acids [<xref ref-type="bibr" rid="RSOB190041C73">73</xref>,<xref ref-type="bibr" rid="RSOB190041C75">75</xref>,<xref ref-type="bibr" rid="RSOB190041C204">204</xref>,<xref ref-type="bibr" rid="RSOB190041C205">205</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). Nevertheless, the macrodomain of TARG1 is very diverged from those in PARG and both MacroD1 and MacroD2 proteins, and adopts a distinct catalytic mechanism [<xref ref-type="bibr" rid="RSOB190041C39">39</xref>].</p>
<p>A distinct homozygous sequence variant of the <italic>TARG1</italic> gene was found in a family with a number of members affected by a severe and progressive neurodegeneration and seizure disorders. The sequence variant associated with disease is characterized by a premature stop codon within the exon 4 of <italic>TARG1</italic> locus and predicts the formation of a truncated and not functional TARG1 enzyme. Importantly, <italic>TARG1</italic> knockdown in human cells leads to significant proliferation defects and sensitivity to DNA damage [<xref ref-type="bibr" rid="RSOB190041C39">39</xref>].</p>
<p>Interestingly, the phenotype of <italic>TARG1</italic>-mutated patients somewhat resembles a clinical case described in the early 1980s of an 8-year-old male who died after a 6-year course of progressive neurologic degeneration and renal failure. Biochemical studies performed on bioptic specimens obtained from this patient showed the lysosomal accumulation of glutamyl ribose 5-phosphate (a glutamate amino acid linked to a phosphoribose group), which was proposed to arise from the inability to cleave the glutamate-linked ADPr on proteins. However, the identity of the deficient gene remained uncovered [<xref ref-type="bibr" rid="RSOB190041C206">206</xref>,<xref ref-type="bibr" rid="RSOB190041C207">207</xref>]. The accumulation of peptides linked to a phosphoribose group (phosphoribosylated peptides) suggests the presence of alternative hydrolytic mechanisms in cells that allow cleavage of the phosphodiester bond within MAR or PAR attached to a protein. Such pathways could intervene both under physiological and pathological conditions; for instance, when not functional hydrolytic enzymes (e.g. in the case of TARG1) lead to an excess and toxic accumulation of MARylated and PARylated proteins. Interestingly, specific members of two unrelated classes of phosphodiesterases were shown to possess ability to produce protein phosphoribosylation <italic>in vitro</italic>, the nucleoside diphosphates linked to X (any moiety) (NUDIX) and ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) [<xref ref-type="bibr" rid="RSOB190041C208">208</xref>–<xref ref-type="bibr" rid="RSOB190041C210">210</xref>].</p>
</sec>
<sec id="s7c">
<label>7.3.</label>
<title>Poly(ADP-ribosyl)glycohydrolase (PARG)</title>
<p>PARG contains a highly diverged macrodomain fold and its structure has been extensively studied [<xref ref-type="bibr" rid="RSOB190041C73">73</xref>,<xref ref-type="bibr" rid="RSOB190041C211">211</xref>–<xref ref-type="bibr" rid="RSOB190041C214">214</xref>]. Distinctly from TARG1, MacroD1 and MacroD2, PARG has an insertion of a unique catalytic loop in the conserved globular macrodomain fold, which contains the catalytic residues and is essential for degradation of PAR chains. PARG preferably binds PAR at the chain termini and sequentially degrades ADP-ribose units (exo-glycohydrolase activity; <xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). The endo-glycohydrolytic cleavage of PAR chains is also catalysed by PARG, but this activity is less efficient [<xref ref-type="bibr" rid="RSOB190041C213">213</xref>,<xref ref-type="bibr" rid="RSOB190041C215">215</xref>,<xref ref-type="bibr" rid="RSOB190041C216">216</xref>]. Yet PARG endo-glycohydrolase activity may become significant in the presence of excessive PAR production, for instance in cells or tissues exposed to abundant oxidative stress as observed in neurological disorders caused by aggregation of cytotoxic proteins (e.g. in PD) [<xref ref-type="bibr" rid="RSOB190041C110">110</xref>]. Indeed, the release of free long PAR fragments was shown to trigger apoptotic signalling [<xref ref-type="bibr" rid="RSOB190041C217">217</xref>].</p>
<p>Although genetic mutations have not been directly linked to human diseases, PARG cellular functions may significantly contribute to the pathogenesis of hereditary and acquired disorders. Contrary to PARP1 inhibition or deletion, which is not lethal for cells and mice (although it increases radiosensitivity), <italic>PARG</italic> knockout results in embryonic lethality in mouse model as a result of PAR accumulation and cellular apoptosis. However, <italic>Parg</italic> null mouse trophoblast-derived stem cells can be successfully cultivated in the presence of PARP inhibitors, suggesting that PARP1 inactivation can rescue <italic>PARG</italic> deletion [<xref ref-type="bibr" rid="RSOB190041C218">218</xref>]. Similarly, <italic>Parg</italic> null <italic>Drosophila melanogaster</italic> flies die at the embryonic stage; however, when grown at a permissive temperature, survival is increased. The surviving flies display PAR accumulation, neurodegeneration, reduced locomotion and premature death [<xref ref-type="bibr" rid="RSOB190041C219">219</xref>]. In line with data obtained in the <italic>D. melanogaster</italic> model, depletion of nuclear <italic>PARG</italic> isoforms in mice results in PAR accumulation in the brain [<xref ref-type="bibr" rid="RSOB190041C220">220</xref>]. Altogether, the body of information provided by <italic>PARG</italic>-deficient models further supports the essential role of PAR in the regulation of cellular homeostasis, especially in neuronal cells.</p>
<p>PARG functions have also been linked with the pathogenesis of inflammatory and neoplastic disorders. As for PARP1, a murine experimental model of colitis shows the contribution of PARG in sustaining the inflammatory response in the colon. Mice harbouring a deletion of the 110-kDa isoform of PARG protein, which are viable and fertile, are resistant to colon injury when challenged by dinitrobenzene sulfonic acid (DNBS) and show an attenuated inflammatory response [<xref ref-type="bibr" rid="RSOB190041C221">221</xref>].</p>
<p>According to experimental models of colitis, the serum titre of antibodies against PARG is a marker of mucosal damage caused by refractory ulcerative colitis [<xref ref-type="bibr" rid="RSOB190041C222">222</xref>].</p>
<p>Database analysis of sequencing data from The Cancer Genome Atlas (TCGA) revealed that <italic>PARG</italic> is overexpressed in many tumour types, in particular in breast tumour tissues, where it appears to be approximately fivefold more expressed than in normal epithelium. Approximately 15% of all invasive ductal breast tumours showed elevated <italic>PARG</italic> mRNA level, with the frequency reaching the 20% in HER2-positive and triple-negative subtypes. Thus, PARG levels are associated with a poor prognosis in breast cancers. Depletion of <italic>PARG</italic> significantly impairs the growth and metastasis of triple-negative breast tumours, in both <italic>in vitro</italic> and <italic>in vivo</italic> models, thus highlighting the therapeutic potential of PARG inhibition in breast cancer [<xref ref-type="bibr" rid="RSOB190041C223">223</xref>]. Importantly, the inhibition of PARG has already been proposed as a therapeutic treatment of human cancers [<xref ref-type="bibr" rid="RSOB190041C10">10</xref>,<xref ref-type="bibr" rid="RSOB190041C224">224</xref>]. This would be particularly appropriate for the treatment of aggressive breast cancers. It is worth mentioning that <italic>PARG</italic> inactivation often occurs as a resistance mechanism to PARP inhibitors in human serous ovarian and triple-negative breast cancers. Indeed, the genetic loss of <italic>PARG</italic> restores PAR formation and partially rescues PARP1 signalling [<xref ref-type="bibr" rid="RSOB190041C225">225</xref>].</p>
</sec>
<sec id="s7d">
<label>7.4.</label>
<title>ADP-ribosyl-acceptor hydrolase 1 (ARH1)</title>
<p>ARH1 is a cytosolic and ubiquitously expressed protein. Although the structure and mechanism are highly similar to ARH3 [<xref ref-type="bibr" rid="RSOB190041C63">63</xref>], ARH1 possesses a robust mono-ADP-ribosyl hydrolytic activity towards <italic>N</italic>-glycosidic bonds of arginine-modified proteins, and no activity against Ser-ADPr [<xref ref-type="bibr" rid="RSOB190041C48">48</xref>,<xref ref-type="bibr" rid="RSOB190041C62">62</xref>,<xref ref-type="bibr" rid="RSOB190041C63">63</xref>,<xref ref-type="bibr" rid="RSOB190041C226">226</xref>,<xref ref-type="bibr" rid="RSOB190041C227">227</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). By using both <italic>in vitro</italic> and <italic>in vivo</italic> models, it was shown that ARH1 plays a role in tumour genesis and progression. Indeed, <italic>Arh1</italic>-deficient mice spontaneously develop multiple malignancies, including lymphoma, hepatocellular carcinoma and hemangio-/rhabdomyosarcoma [<xref ref-type="bibr" rid="RSOB190041C228">228</xref>]. Studies performed in <italic>Arh1</italic> heterozygous mice and in nude mice injected with <italic>Arh1</italic>-null MEFs showed the loss of heterozygosity (LOH) of the remaining <italic>Arh1</italic> allele or loss of <italic>Arh1</italic> gene activity due to spontaneous mutagenesis. Genome sequencing of mice revealed that <italic>Arh1</italic> gene mutations were located in exons encoding the catalytic site. Analysis of human cancer COSMIC database revealed 32 <italic>ARH1</italic> mutations found in human lung, breast and colon cancers; 70% of those mutations were missense mutations with single-base substitution, which surprisingly overlap with the mutations that spontaneously generate in <italic>Arh1</italic> heterozygous mice [<xref ref-type="bibr" rid="RSOB190041C21">21</xref>]. Among those mutations, the D56N hits one of the two conserved aspartates (positions 60 and 61 in mouse Arh1) that are required for Mg<sup>2+</sup> coordination and hydrolase activity [<xref ref-type="bibr" rid="RSOB190041C63">63</xref>,<xref ref-type="bibr" rid="RSOB190041C229">229</xref>].</p>
</sec>
<sec id="s7e">
<label>7.5.</label>
<title>ADP-ribosyl-acceptor hydrolase 3 (ARH3)</title>
<p>ARH3 was initially identified as a back-up PAR-degrading enzyme. Similar to PARG, ARH3 primarily cleaves the chains as exo-glycohydrolase, however, its specific activity against long PAR chains is nearly two levels of magnitude lower than for PARG [<xref ref-type="bibr" rid="RSOB190041C62">62</xref>,<xref ref-type="bibr" rid="RSOB190041C63">63</xref>,<xref ref-type="bibr" rid="RSOB190041C66">66</xref>,<xref ref-type="bibr" rid="RSOB190041C230">230</xref>]. Later on, ARH3 was shown to be the main hydrolase responsible for cleaving the ADPr from modified serine residues [<xref ref-type="bibr" rid="RSOB190041C66">66</xref>,<xref ref-type="bibr" rid="RSOB190041C231">231</xref>] (<xref ref-type="fig" rid="RSOB190041F1">figure 1</xref>). The catalytic fold of ARH3 is completely different compared with PARG, which is instead a macrodomain-containing protein. In turn, the structural divergence reflects in a different conformation of ADP-ribose within the catalytic pocket as well as in a different catalytic mechanism [<xref ref-type="bibr" rid="RSOB190041C63">63</xref>,<xref ref-type="bibr" rid="RSOB190041C232">232</xref>–<xref ref-type="bibr" rid="RSOB190041C234">234</xref>]. As for ARH1, the presence of conserved aspartates (D77 and D78 in human ARH3), are essential for coordination of Mg<sup>2+</sup> within ARH hydrolase [<xref ref-type="bibr" rid="RSOB190041C229">229</xref>].</p>
<p>At the cellular level, most of the ARH3 is found in cytoplasm, nucleus and mitochondria. The mitochondrial localization of ARH3 is determined by the presence of a mitochondrial-targeting sequence at the N-terminus, which suggests a role for ARH3 for ADPr degradation in mitochondria [<xref ref-type="bibr" rid="RSOB190041C230">230</xref>,<xref ref-type="bibr" rid="RSOB190041C235">235</xref>]. Nevertheless, all the ARH3 cellular functions described so far seem to converge on safeguarding genome stability. As discussed above, Ser-ADPr is the most abundant type of ADPr modification in response to genotoxic stress and it can be reversed only by ARH3, as far as we know. ARH3 is indeed able to cleave the terminal <italic>O</italic>-glycosidic bond joining the ADP-ribose and the serine of modified protein substrates [<xref ref-type="bibr" rid="RSOB190041C66">66</xref>,<xref ref-type="bibr" rid="RSOB190041C85">85</xref>]. ARH3 was also shown to act on free oligomers of PAR in cells released upon PARG endoglycohydrolase activity [<xref ref-type="bibr" rid="RSOB190041C236">236</xref>,<xref ref-type="bibr" rid="RSOB190041C237">237</xref>]. By doing so, ARH3 may control a mechanism of PARP1/PAR/AIF-mediated cell death (also known as Parthanatos) [<xref ref-type="bibr" rid="RSOB190041C236">236</xref>]. Altogether these data support the hypothesis that ARH3 could be involved in the pathogenesis of human disorders characterized by the cytotoxic and pro-apoptotic accumulation of PAR, such as in neurological disorders (e.g. in PD and AD).</p>
<p>Importantly, autosomal-recessive inherited genetic variants of ARH3 are directly linked with neurodegenerative disorders. Two independent studies have described 28 individuals belonging to fourteen families, which associate recessive and inactivating <italic>ARH3</italic> gene mutations with paediatric-onset neurodegenerative disorder characterized by brain atrophy, developmental delay or regression, seizures, infection-associated episodes of ataxia, and axonal sensori-motor neuropathy [<xref ref-type="bibr" rid="RSOB190041C22">22</xref>,<xref ref-type="bibr" rid="RSOB190041C23">23</xref>]. It should be noted that most of the detected truncations/mutations predictably affect protein stability. As expected, ARH3 deficiencies associate with the accumulation of cellular ADPr, which drastically affects cell viability. Both the cellular accumulation of ADPr and the following cell death are prevented by treatment with PARP inhibitors [<xref ref-type="bibr" rid="RSOB190041C22">22</xref>,<xref ref-type="bibr" rid="RSOB190041C23">23</xref>]. Thus, these results propose once again the inhibition of PARP1 as a therapeutic strategy for the treatment of neurodegenerative diseases.</p>
<p>It is worth mentioning that, although all <italic>ARH3</italic> patients show overall overlapping clinical features, both studies have not established an obvious genotype–phenotype correlation, for instance, regarding the onset and additional complications of the disorder. This observation suggests that additional factors, such as the genetic background or the exposure to environmental challenges, may contribute to the phenotypic variability among individuals. Considering the crucial roles of ARH3 in response to cellular stresses (e.g. oxidative and DNA damage insults), the exposure to stress conditions may be particularly important to anticipate the onset or worsen the neurodegenerative traits of disease.</p>
</sec>
</sec>
<sec id="s8">
<label>8.</label>
<title>Additional macrodomain-containing proteins in human disease</title>
<sec id="s8a">
<label>8.1.</label>
<title>GDAP2 (MacroD3)</title>
<p><italic>GDAP2</italic> gene (found in metazoans and plants) encodes an uncharacterized additional macrodomain-containing protein, which has been recently linked to a human hereditary disorder characterized by ataxia, progressive spasticity and dementia [<xref ref-type="bibr" rid="RSOB190041C24">24</xref>]. Although GDAP2 macrodomain is similar to the one of MacroD1/2 proteins, it does not seem to bind derivatives of ADP-ribose, but instead, it appears to possess some affinity for poly(A) [<xref ref-type="bibr" rid="RSOB190041C69">69</xref>,<xref ref-type="bibr" rid="RSOB190041C72">72</xref>]. Yet the pathogenic mechanisms underlying GDAP2 deficiency remain unclear.</p>
</sec>
<sec id="s8b">
<label>8.2.</label>
<title>ALC1 (CHD1L)</title>
<p>The human ALC1 (amplified in liver cancer 1; also known as CHD1L (chromodomain-helicase-DNA-binding protein 1-like) gene encodes a member of the SNF2 (sucrose non-fermenter 2) superfamily of ATPases. Among SNF2 family members, ALC1 is unique because it includes a macrodomain that is capable of binding PAR. The binding of ALC1 to activated and PARylated PARP1 is crucial, but not sufficient, for DNA-dependent ATPase and ATP-dependent nucleosome remodelling activities [<xref ref-type="bibr" rid="RSOB190041C238">238</xref>–<xref ref-type="bibr" rid="RSOB190041C243">243</xref>].</p>
<p>ALC1 was originally identified as a gene amplified in hepatocellular carcinomas [<xref ref-type="bibr" rid="RSOB190041C18">18</xref>]. Overexpression of the ALC1 protein was found to transform human cells and to be oncogenic in mice [<xref ref-type="bibr" rid="RSOB190041C18">18</xref>,<xref ref-type="bibr" rid="RSOB190041C244">244</xref>,<xref ref-type="bibr" rid="RSOB190041C245">245</xref>]. A role for the oncogene ALC1 has also been demonstrated in breast and CRC [<xref ref-type="bibr" rid="RSOB190041C19">19</xref>,<xref ref-type="bibr" rid="RSOB190041C20">20</xref>].</p>
<p>In addition, gene mutations in human <italic>ALC1</italic> were found in patients affected by congenital anomalies of the kidney and urinary tract [<xref ref-type="bibr" rid="RSOB190041C246">246</xref>].</p>
</sec>
</sec>
<sec id="s9">
<label>9.</label>
<title>ADPr and infectious disease</title>
<p>From the perspective of human pathologies bacterial ADPr systems can roughly be divided into two groups: the secreted exotoxins, which participate directly in promoting bacterial infection and associated symptoms; and those that have an internal role in bacterial stress-response. The latter potentially have major functions in persistence and have been proposed as potential therapeutic targets.</p>
<p>The exotoxins group encompasses a variety of bacterial ADP-ribosyl transferase toxins (bARTTs). MARylation of eukaryotic targets by bARTT is usually irreversible and aims at nucleotide-binding proteins, prevalently GTP- and, in some cases, ATP-binding proteins [<xref ref-type="bibr" rid="RSOB190041C44">44</xref>]. Interestingly, the deficiency of human ARH1 hydrolase leads to an increased sensitivity to cholera toxin, suggesting that bacterial ADPr can be reversed by the host hydrolases [<xref ref-type="bibr" rid="RSOB190041C65">65</xref>].</p>
<p>As outlined in §2 of this review, two subfamilies of bARTTs can be distinguished based on their structure and target proteins: diphtheria-like and cholera-like toxins, the latter encompassing an additional two subgroups, C2-like binary and C3-like toxins.</p>
<p>Diphtheria toxin ADP-ribosylates the eukaryotic elongation factor 2 (EF2), a GTP-binding protein essential for protein synthesis in the cell. The modification halts the entire protein synthesis and, in turn, leads to cell death [<xref ref-type="bibr" rid="RSOB190041C44">44</xref>]. The same mechanism of action is shared by the Exotoxin A from <italic>Pseudomonas aeruginosa</italic>, a ubiquitous multidrug-resistant pathogen [<xref ref-type="bibr" rid="RSOB190041C247">247</xref>].</p>
<p>Cholera and cholera-toxin-like proteins (e.g. the heat-labile enterotoxin from <italic>Escherichia coli</italic> and the pertussis toxin from <italic>Bordetella pertussis</italic>) transfer ADP-ribose onto heterotrimeric G proteins. The modification locks the subunit α of G proteins in a GTP-bound state, which constitutively stimulates host adenylate cyclase. In the case of cholera and enterotoxin, constitutive activation of G proteins results in opening and efflux of the chloride ions together with water [<xref ref-type="bibr" rid="RSOB190041C44">44</xref>]. Pertussis toxin acts towards virtually all mammalian cell types and has a broad array of effects on host cell activities [<xref ref-type="bibr" rid="RSOB190041C248">248</xref>]. ADP-ribosyl transferase subunit of typhoid toxin from <italic>Salmonella typhi</italic> (exclusively human pathogen) is structurally similar to pertussis toxin; however, the pathogenic mechanisms as well as the proteins substrate(s) of this toxin remain unknown [<xref ref-type="bibr" rid="RSOB190041C249">249</xref>].</p>
<p>The C2-like toxins from <italic>Clostridium</italic> sp<italic>.</italic> [<xref ref-type="bibr" rid="RSOB190041C44">44</xref>,<xref ref-type="bibr" rid="RSOB190041C250">250</xref>] and the newly characterized SpvB from <italic>Salmonella</italic> sp<italic>.</italic> [<xref ref-type="bibr" rid="RSOB190041C251">251</xref>] are examples of toxins ADP-ribosylating non-polymerized form of actin. The MARylated G-actin, upon incorporation into filaments, inhibits further integrations resulting in serious impairments of cellular cytoskeleton.</p>
<p>The C3-like toxins expressed by <italic>Clostridium botulinum</italic>, <italic>Bacillus cereus</italic>, <italic>Staphylococcus aureus</italic> and others target small Rho GTPase enzymes, which modulate actin polymerization. The MARylation of Rho GTPase alters the interaction with protein partners, thus locking themselves in a deactivated state. The consequences are similar to that of the C2-like toxins—the disintegration of the cytoskeleton. The recently described SpyA from <italic>Streptococcus pyogenes</italic> targets another cytoskeletal protein-vimentin, and actin to a lesser degree [<xref ref-type="bibr" rid="RSOB190041C252">252</xref>].</p>
<p>In addition, a very intriguing class of bARTTs has been described in <italic>Legionella pneumophila</italic>. The <italic>Legionella</italic> protein SdeA modifies ubiquitin molecules of the host by transferring ADPr on arginine 42, thus impairing the physiological ubiquitination processes. Through a process of phosphoribosyl-ubiquitination, MARylated ubiquitin is in turn transferred onto serine residues of protein substrates, therefore modulating the endogenous functions of modified proteins, such as Rab33 [<xref ref-type="bibr" rid="RSOB190041C253">253</xref>–<xref ref-type="bibr" rid="RSOB190041C255">255</xref>]. This ADPr system is reversible, as it can be counteracted by another bacterial protein, SidJ, acting as a hydrolase [<xref ref-type="bibr" rid="RSOB190041C256">256</xref>].</p>
<p>One of the best-studied stress-response systems in bacteria is the toxin-antitoxin (TA) module. There are more than 1000 TA modules known [<xref ref-type="bibr" rid="RSOB190041C257">257</xref>]. Among them, the only known module to exploit the ADPr system is the DarT/DarG module, which is found in various bacteria, including the global pathogen <italic>Mycobacterium tuberculosis</italic> [<xref ref-type="bibr" rid="RSOB190041C258">258</xref>]. DarT is an ART able to MARylate the single-stranded DNA on specific thymidine residues, which impairs cellular processes essential for bacterial growth and activates SOS response. The macrodomain protein DarG, which hydrolyses the ADP-ribosylated DNA, counteracts DarT activity [<xref ref-type="bibr" rid="RSOB190041C258">258</xref>].</p>
<p>Another example of ADPr system in bacterial stress response is operated by sirtuins. While the mammalian sirtuins seem to act primarily as NAD-dependent deacetylases, a diverged class of sirtuins present in pathogenic bacteria and fungi (called SirTMs) exhibits a robust protein ADPr activity that is regulated by another protein modification: lipoylation. This mechanism was shown to modulate the microbial oxidative stress response [<xref ref-type="bibr" rid="RSOB190041C259">259</xref>].</p>
</sec>
<sec id="s10">
<label>10.</label>
<title>ADPr in viral infections</title>
<p>Viruses from the <italic>Coronaviridae</italic>, <italic>Togaviridae</italic> and <italic>Hepeviridae</italic> families all contain genes encoding macrodomain-containing proteins, suggesting a role for ADPr during infection diseases [<xref ref-type="bibr" rid="RSOB190041C260">260</xref>–<xref ref-type="bibr" rid="RSOB190041C265">265</xref>]. Notably, several human PARPs have been shown to be activated and function in the host antiviral response. For instance, PARPs 9, 12, 13 and 14 are among the 62 Interferon-stimulated genes and overexpression of PARPs 7, 10 or 12 inhibits alphavirus replication [<xref ref-type="bibr" rid="RSOB190041C266">266</xref>]. In addition, PARPs 5a, 12, 13, 14 and 15 localize at the stress granules, well-known cytoplasmic structures with antiviral functions; interestingly, the integrity of stress granules is inhibited by the alphaviral macrodomain-containing nsP3 [<xref ref-type="bibr" rid="RSOB190041C138">138</xref>,<xref ref-type="bibr" rid="RSOB190041C267">267</xref>]. Thus, it appears that ADPr is required for a proper host antiviral response and that viruses have evolved systems (mainly consisting of macrodomain-containing proteins) able to modulate defensive host ADPr systems. Not surprisingly, PARPs 4, 9, 13, 14 and 15 show a rapid evolution as a result of a strong recurrent positive selection in the attempt to escape the modulation operated by viral proteins [<xref ref-type="bibr" rid="RSOB190041C268">268</xref>,<xref ref-type="bibr" rid="RSOB190041C269">269</xref>].</p>
</sec>
<sec id="s11">
<label>11.</label>
<title>Concluding remarks</title>
<p>Numerous pioneering findings have shown the impact of ADPr on many vital cellular processes, the dysregulation of which is known to lead to human disorders. Many genes involved in ADPr are now known to be mutated or dysregulated in various acquired and hereditary diseases, such as neurological disorders and cancer. By contrast, the pharmacological modulation of ADPr by small-molecule inhibitors can be a potent tool to treat human diseases. Research within the ADPr field has been progressing particularly fast in recent years, and it is hoped that this will provide new avenues for the therapeutic interventions.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="d35e167">
<caption>
<title>Reviewer comments</title>
</caption>
<media mime-subtype="pdf" mimetype="application" xlink:href="rsob190041_review_history.pdf"></media>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors thank Kerryanne Crawford (University of Oxford) and Giuliana Catara (Institute of Protein Biochemistry) for helpful comments on the manuscript.</p>
</ack>
<sec id="s12">
<title>Data accessibility</title>
<p>This article has no additional data.</p>
</sec>
<sec id="s13" sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare no competing interests.</p>
</sec>
<sec id="s14">
<title>Funding</title>
<p>L.P. was supported by a fellowship from the Italian Foundation for Cancer Research (FIRC, Milan, Italy; grant no. 14895). P.M. and A.M. are supported by the Croatian Science Foundation (IP-2016-06-4242). Work in I.A.'s laboratory is supported by Wellcome Trust (grant nos. 101794 and 210634) and Cancer Research United Kingdom (grant no. C35050/A22284).</p>
</sec>
<ref-list>
<title>References</title>
<ref id="RSOB190041C1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>ON</given-names></name></person-group>
<year>2006</year>
<article-title>Interpreting the protein language using proteomics</article-title>. <source/>Nat. Rev. Mol. Cell Biol.
<volume>7</volume>, <fpage>391</fpage>–<lpage>403</lpage>. (<pub-id pub-id-type="doi">10.1038/nrm1939</pub-id>)<pub-id pub-id-type="pmid">16723975</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palazzo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mikoč</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2017</year>
<article-title>ADP-ribosylation: new facets of an ancient modification</article-title>. <source/>FEBS J.
<volume>284</volume>, <fpage>2932</fpage>–<lpage>2946</lpage>. (<pub-id pub-id-type="doi">10.1111/febs.14078</pub-id>)<pub-id pub-id-type="pmid">28383827</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lüscher</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bütepage</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Eckei</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Krieg</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Verheugd</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Shilton</surname><given-names>BH</given-names></name></person-group>
<year>2018</year>
<article-title>ADP-ribosylation, a multifaceted posttranslational modification involved in the control of cell physiology in health and disease</article-title>. <source/>Chem. Rev.
<volume>118</volume>, <fpage>1092</fpage>–<lpage>1136</lpage>. (<pub-id pub-id-type="doi">10.1021/acs.chemrev.7b00122</pub-id>)<pub-id pub-id-type="pmid">29172462</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ringel</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Tucker</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Haigis</surname><given-names>MC</given-names></name></person-group>
<year>2018</year>
<article-title>Chemical and physiological features of mitochondrial acylation</article-title>. <source/>Mol. Cell.
<volume>72</volume>, <fpage>610</fpage>–<lpage>624</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2018.10.023</pub-id>)<pub-id pub-id-type="pmid">30444998</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chambon</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Weill</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Mandel</surname><given-names>P</given-names></name></person-group>
<year>1963</year>
<article-title>Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>11</volume>, <fpage>39</fpage>–<lpage>43</lpage>. (<pub-id pub-id-type="doi">10.1016/0006-291X(63)90024-X</pub-id>)<pub-id pub-id-type="pmid">14019961</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chambon</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Weill</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Strosser</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Mandel</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Doly</surname><given-names>J</given-names></name></person-group>
<year>1966</year>
<article-title>On the formation of a novel adenylic compound by enzymatic extracts of liver nuclei</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>25</volume>, <fpage>638</fpage>–<lpage>643</lpage>. (<pub-id pub-id-type="doi">10.1016/0006-291X(66)90502-X</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishizuka</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ueda</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nakazawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hayaishi</surname><given-names>O</given-names></name></person-group>
<year>1967</year>
<article-title>Studies on the polymer of adenosine diphosphate ribose. I. Enzymic formation from nicotinamide adenine dinuclotide in mammalian nuclei</article-title>. <source/>J. Biol. Chem.
<volume>242</volume>, <fpage>3164</fpage>–<lpage>3171</lpage>.<pub-id pub-id-type="pmid">4291072</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugimura</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fujimura</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hasegawa</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kawamura</surname><given-names>Y</given-names></name></person-group>
<year>1967</year>
<article-title>Polymerization of the adenosine 5′-diphosphate ribose moiety of nad by rat liver nuclear enzyme</article-title>. <source/>Biochim. Biophys. Acta Nucleic Acids Protein Synth.
<volume>138</volume>, <fpage>438</fpage>–<lpage>441</lpage>. (<pub-id pub-id-type="doi">10.1016/0005-2787(67)90507-2</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lord</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Ashworth</surname><given-names>A</given-names></name></person-group>
<year>2017</year>
<article-title>PARP inhibitors: Synthetic lethality in the clinic</article-title>. <source/>Science
<volume>355</volume>, <fpage>1152</fpage>–<lpage>1158</lpage>. (<pub-id pub-id-type="doi">10.1126/science.aam7344</pub-id>)<pub-id pub-id-type="pmid">28302823</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palazzo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2018</year>
<article-title>PARPs in genome stability and signal transduction: implications for cancer therapy</article-title>. <source/>Biochem. Soc. Trans.
<volume>46</volume>, <fpage>1681</fpage>–<lpage>1695</lpage>. (<pub-id pub-id-type="doi">10.1042/BST20180418</pub-id>)<pub-id pub-id-type="pmid">30420415</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguiar</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Takeyama</surname><given-names>K</given-names></name>, <name name-style="western"><surname>He</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kreinbrink</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Shipp</surname><given-names>MA</given-names></name></person-group>
<year>2005</year>
<article-title>B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity</article-title>. <source/>J. Biol. Chem.
<volume>280</volume>, <fpage>33 756</fpage>–<lpage>33 765</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M505408200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguiar</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Yakushijin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kharbanda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Salgia</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fletcher</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Shipp</surname><given-names>MA</given-names></name></person-group>
<year>2000</year>
<article-title>BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration</article-title>. <source/>Blood
<volume>96</volume>, <fpage>4328</fpage>–<lpage>4334</lpage>.<pub-id pub-id-type="pmid">11110709</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hua</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Jing</surname><given-names>J</given-names></name></person-group>
<year>2018</year>
<article-title>PARP9 is overexpressed in human breast cancer and promotes cancer cell migration</article-title>. <source/>Oncol. Lett.
<volume>16</volume>, <fpage>4073</fpage>–<lpage>4077</lpage>. (<pub-id pub-id-type="doi">10.3892/ol.2018.9124</pub-id>)<pub-id pub-id-type="pmid">30128030</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Goenka</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Henttinen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gudapati</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Reinikainen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Eischen</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Lahesmaa</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Boothby</surname><given-names>M</given-names></name></person-group>
<year>2009</year>
<article-title>PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells</article-title>. <source/>Blood
<volume>113</volume>, <fpage>2416</fpage>–<lpage>2425</lpage>. (<pub-id pub-id-type="doi">10.1182/blood-2008-03-144121</pub-id>)<pub-id pub-id-type="pmid">19147789</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yanagawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Funasaka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tsutsumi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Watanabe</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Raz</surname><given-names>A</given-names></name></person-group>
<year>2007</year>
<article-title>Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) polymerase family-14</article-title>. <source/>Cancer Res.
<volume>67</volume>, <fpage>8682</fpage>–<lpage>8689</lpage>. (<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1586</pub-id>)<pub-id pub-id-type="pmid">17875708</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehrotra</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Riley</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Voss</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Goenka</surname><given-names>S</given-names></name></person-group>
<year>2011</year>
<article-title>PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation</article-title>. <source/>J. Biol. Chem.
<volume>286</volume>, <fpage>1767</fpage>–<lpage>1776</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M110.157768</pub-id>)<pub-id pub-id-type="pmid">21081493</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iansante</surname><given-names>V</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation</article-title>. <source/>Nat. Commun.
<volume>6</volume>, <fpage>7882</fpage> (<pub-id pub-id-type="doi">10.1038/ncomms8882</pub-id>)<pub-id pub-id-type="pmid">26258887</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>NF</given-names></name><etal>et al.</etal></person-group>
<year>2008</year>
<article-title>Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma</article-title>. <source/>Hepatology
<volume>47</volume>, <fpage>503</fpage>–<lpage>510</lpage>. (<pub-id pub-id-type="doi">10.1002/hep.22072</pub-id>)<pub-id pub-id-type="pmid">18023026</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu</surname><given-names>QJ</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>CG</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>XZ</given-names></name></person-group>
<year>2015</year>
<article-title>Chromodomain helicase/ATPase DNA-binding protein 1-like gene (CHD1 L) expression and implications for invasion and metastasis of breast cancer</article-title>. <source/>PLoS ONE
<volume>10</volume>, <fpage>e0143030</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0143030</pub-id>)<pub-id pub-id-type="pmid">26599012</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>X</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>CHD1 L promotes tumor progression and predicts survival in colorectal carcinoma</article-title>. <source/>J. Surg. Res.
<volume>185</volume>, <fpage>84</fpage>–<lpage>91</lpage>. (<pub-id pub-id-type="doi">10.1016/j.jss.2013.05.008</pub-id>)<pub-id pub-id-type="pmid">23746766</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vekhter</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Heath</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Barbieri</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>J</given-names></name></person-group>
<year>2015</year>
<article-title>Mutations of the functional ARH1 allele in tumors from ARH1 heterozygous mice and cells affect ARH1 catalytic activity, cell proliferation and tumorigenesis</article-title>. <source/>Oncogenesis
<volume>4</volume>, <fpage>e151</fpage> (<pub-id pub-id-type="doi">10.1038/oncsis.2015.5</pub-id>)<pub-id pub-id-type="pmid">26029825</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danhauser</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Bi-allelic ADPRHL2 mutations cause neurodegeneration with developmental delay, ataxia, and axonal neuropathy</article-title>. <source/>Am. J. Hum. Genet.
<volume>103</volume>, <fpage>817</fpage>–<lpage>825</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ajhg.2018.10.005</pub-id>)<pub-id pub-id-type="pmid">30401461</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>SG</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Biallelic mutations in ADPRHL2, encoding ADP-ribosylhydrolase 3, lead to a degenerative pediatric stress-induced epileptic ataxia syndrome</article-title>. <source/>Am. J. Hum. Genet.
<volume>103</volume>, <fpage>431</fpage>–<lpage>439</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ajhg.2018.07.010</pub-id>)<pub-id pub-id-type="pmid">30100084</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eidhof</surname><given-names>I</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>GDAP2 mutations implicate susceptibility to cellular stress in a new form of cerebellar ataxia</article-title>. <source/>Brain
<volume>141</volume>, <fpage>2592</fpage>–<lpage>2604</lpage>. (<pub-id pub-id-type="doi">10.1093/brain/awy198</pub-id>)<pub-id pub-id-type="pmid">30084953</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>YG</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Si</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>ZQ</given-names></name>, <name name-style="western"><surname>Mu</surname><given-names>YM</given-names></name></person-group>
<year>2007</year>
<article-title>Induction of the LRP16 gene by estrogen promotes the invasive growth of Ishikawa human endometrial cancer cells through the downregulation of E-cadherin</article-title>. <source/>Cell Res.
<volume>17</volume>, <fpage>869</fpage>–<lpage>880</lpage>. (<pub-id pub-id-type="doi">10.1038/cr.2007.79</pub-id>)<pub-id pub-id-type="pmid">17893710</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>YZ</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>WD</given-names></name></person-group>
<year>2009</year>
<article-title>Clinicopathological significance of LRP16 protein in 336 gastric carcinoma patients</article-title>. <source/>World J. Gastroenterol.
<volume>15</volume>, <fpage>4833</fpage>–<lpage>4837</lpage>. (<pub-id pub-id-type="doi">10.3748/wjg.15.4833</pub-id>)<pub-id pub-id-type="pmid">19824120</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xi</surname><given-names>HQ</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>WD</given-names></name></person-group>
<year>2010</year>
<article-title>Clinicopathological significance and prognostic value of LRP16 expression in colorectal carcinoma</article-title>. <source/>World J. Gastroenterol.
<volume>16</volume>, <fpage>1644</fpage>–<lpage>1648</lpage>. (<pub-id pub-id-type="doi">10.3748/wjg.v16.i13.1644</pub-id>)<pub-id pub-id-type="pmid">20355243</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>An</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Mei</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Bai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hanski</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ahola</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>W</given-names></name></person-group>
<year>2017</year>
<article-title>Blockade of the LRP16-PKR-NF-κB signaling axis sensitizes colorectal carcinoma cells to DNA-damaging cytotoxic therapy</article-title>. <source/>Elife
<volume>6</volume>, <fpage>e27301</fpage> (<pub-id pub-id-type="doi">10.7554/eLife.27301</pub-id>)<pub-id pub-id-type="pmid">28820388</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>DX</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Pu</surname><given-names>YD</given-names></name>, <name name-style="western"><surname>Mu</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>XH</given-names></name></person-group>
<year>2006</year>
<article-title>Expression and clinical significance of LRP16 gene in human breast cancer</article-title>. <source/>Ai Zheng.
<volume>25</volume>, <fpage>866</fpage>–<lpage>870</lpage>.<pub-id pub-id-type="pmid">16831279</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>W</given-names></name></person-group>
<year>2010</year>
<article-title>Clinicopathological significance and prognostic value of leukemia-related protein 16 expression in invasive ductal breast carcinoma</article-title>. <source/>Cancer Sci.
<volume>101</volume>, <fpage>2262</fpage>–<lpage>2268</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1349-7006.2010.01658.x</pub-id>)<pub-id pub-id-type="pmid">20649898</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anney</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<year>2010</year>
<article-title>A genome-wide scan for common alleles affecting risk for autism</article-title>. <source/>Hum. Mol. Genet.
<volume>19</volume>, <fpage>4072</fpage>–<lpage>4082</lpage>. (<pub-id pub-id-type="doi">10.1093/hmg/ddq307</pub-id>)<pub-id pub-id-type="pmid">20663923</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsang</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Croen</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Torres</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Kharrazi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Delorenze</surname><given-names>GN</given-names></name>, <name name-style="western"><surname>Windham</surname><given-names>GC</given-names></name>, <name name-style="western"><surname>Yoshida</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Zerbo</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>LA</given-names></name></person-group>
<year>2013</year>
<article-title>A genome-wide survey of transgenerational genetic effects in autism</article-title>. <source/>PLoS ONE
<volume>8</volume>, <fpage>e76978</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0076978</pub-id>)<pub-id pub-id-type="pmid">24204716</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Cadby</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Blangero</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Abraham</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Whitehouse</surname><given-names>AJO</given-names></name>, <name name-style="western"><surname>Moses</surname><given-names>EK</given-names></name></person-group>
<year>2014</year>
<article-title>MACROD2 gene associated with autistic-like traits in a general population sample</article-title>. <source/>Psychiatr. Genet.
<volume>24</volume>, <fpage>241</fpage>–<lpage>248</lpage>. (<pub-id pub-id-type="doi">10.1097/YPG.0000000000000052</pub-id>)<pub-id pub-id-type="pmid">25360606</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maas</surname><given-names>NM</given-names></name><etal>et al.</etal></person-group>
<year>2007</year>
<article-title>The C20orf133 gene is disrupted in a patient with Kabuki syndrome</article-title>. <source/>J. Med. Genet.
<volume>44</volume>, <fpage>562</fpage>–<lpage>569</lpage>. (<pub-id pub-id-type="doi">10.1136/jmg.2007.049510</pub-id>)<pub-id pub-id-type="pmid">17586838</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuniba</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<year>2009</year>
<article-title>Molecular karyotyping in 17 patients and mutation screening in 41 patients with Kabuki syndrome</article-title>. <source/>J. Hum. Genet.
<volume>54</volume>, <fpage>304</fpage>–<lpage>309</lpage>. (<pub-id pub-id-type="doi">10.1038/jhg.2009.30</pub-id>)<pub-id pub-id-type="pmid">19343044</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beroukhim</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<year>2010</year>
<article-title>The landscape of somatic copy-number alteration across human cancers</article-title>. <source/>Nature
<volume>463</volume>, <fpage>899</fpage>–<lpage>905</lpage>. (<pub-id pub-id-type="doi">10.1038/nature08822</pub-id>)<pub-id pub-id-type="pmid">20164920</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dulak</surname><given-names>AM</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis</article-title>. <source/>Cancer Res.
<volume>72</volume>, <fpage>4383</fpage>–<lpage>4393</lpage>. (<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3893</pub-id>)<pub-id pub-id-type="pmid">22751462</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakthianandeswaren</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>MACROD2 haploinsufficiency impairs catalytic activity of PARP1 and promotes chromosome instability and growth of intestinal tumors</article-title>. <source/>Cancer Discov.
<volume>8</volume>, <fpage>988</fpage>–<lpage>1005</lpage>. (<pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0909</pub-id>)<pub-id pub-id-type="pmid">29880585</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharifi</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease</article-title>. <source/>EMBO J.
<volume>32</volume>, <fpage>1225</fpage>–<lpage>1237</lpage>. (<pub-id pub-id-type="doi">10.1038/emboj.2013.51</pub-id>)<pub-id pub-id-type="pmid">23481255</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hottiger</surname><given-names>MO</given-names></name>, <name name-style="western"><surname>Hassa</surname><given-names>PO</given-names></name>, <name name-style="western"><surname>Luscher</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Schuler</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Koch-Nolte</surname><given-names>F</given-names></name></person-group>
<year>2010</year>
<article-title>Toward a unified nomenclature for mammalian Adp-ribosyltransferases</article-title>. <source/>Trends Biochem. Sci.
<volume>35</volume>, <fpage>208</fpage>–<lpage>219</lpage>. (<pub-id pub-id-type="doi">10.1016/j.tibs.2009.12.003</pub-id>)<pub-id pub-id-type="pmid">20106667</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>P</given-names></name></person-group>
<year>2018</year>
<article-title>Insights into the biogenesis, function, and regulation of ADP-ribosylation</article-title>. <source/>Nat. Chem. Biol.
<volume>14</volume>, <fpage>236</fpage>–<lpage>243</lpage>. (<pub-id pub-id-type="doi">10.1038/nchembio.2568</pub-id>)<pub-id pub-id-type="pmid">29443986</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barkauskaite</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Jankevicius</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2015</year>
<article-title>Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADP-ribosylation</article-title>. <source/>Mol. Cell.
<volume>58</volume>, <fpage>935</fpage>–<lpage>946</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2015.05.007</pub-id>)<pub-id pub-id-type="pmid">26091342</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassel</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pfeuffer</surname><given-names>T</given-names></name></person-group>
<year>1978</year>
<article-title>Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>75</volume>, <fpage>2669</fpage>–<lpage>2673</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.75.6.2669</pub-id>)<pub-id pub-id-type="pmid">208069</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Aktories</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Barbieri</surname><given-names>JT</given-names></name></person-group>
<year>2014</year>
<article-title>Novel bacterial ADP-ribosylating toxins: structure and function</article-title>. <source/>Nat. Rev. Microbiol.
<volume>12</volume>, <fpage>599</fpage>–<lpage>611</lpage>. (<pub-id pub-id-type="doi">10.1038/nrmicro3310</pub-id>)<pub-id pub-id-type="pmid">25023120</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vyas</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Matic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Uchima</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Rood</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zaja</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hay</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>P</given-names></name></person-group>
<year>2014</year>
<article-title>Family-wide analysis of poly(ADP-ribose) polymerase activity</article-title>. <source/>Nat Commun.
<volume>5</volume>, <fpage>4426</fpage> (<pub-id pub-id-type="doi">10.1038/ncomms5426</pub-id>)<pub-id pub-id-type="pmid">25043379</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Ness</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Howard</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Bodley</surname><given-names>JW</given-names></name></person-group>
<year>1980</year>
<article-title>ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products</article-title>. <source/>J. Biol. Chem.
<volume>255</volume>, <fpage>10 717</fpage>–<lpage>10 720</lpage>.</mixed-citation>
</ref>
<ref id="RSOB190041C47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koch-Nolte</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kernstock</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mueller-Dieckmann</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Haag</surname><given-names>F</given-names></name></person-group>
<year>2008</year>
<article-title>Mammalian ADP-ribosyltransferases and ADP-ribosylhydrolases</article-title>. <source/>Front. Biosci.
<volume>13</volume>, <fpage>6716</fpage>–<lpage>6729</lpage>. (<pub-id pub-id-type="doi">10.2741/3184</pub-id>)<pub-id pub-id-type="pmid">18508690</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laing</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Unger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Koch-Nolte</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Haag</surname><given-names>F</given-names></name></person-group>
<year>2011</year>
<article-title>Adp-ribosylation of arginine</article-title>. <source/>Amino Acids
<volume>41</volume>, <fpage>257</fpage>–<lpage>269</lpage>. (<pub-id pub-id-type="doi">10.1007/s00726-010-0676-2</pub-id>)<pub-id pub-id-type="pmid">20652610</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hay</surname><given-names>RT</given-names></name></person-group>
<year>2012</year>
<article-title>Reanalysis of phosphoproteomics data uncovers ADP-ribosylation sites</article-title>. <source/>Nat. Methods
<volume>9</volume>, <fpage>771</fpage>–<lpage>772</lpage>. (<pub-id pub-id-type="doi">10.1038/nmeth.2106</pub-id>)<pub-id pub-id-type="pmid">22847107</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabrizio</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Di Paola</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Stilla</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Giannotta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ruggiero</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Menzel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Koch-Nolte</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Sallese</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Di Girolamo</surname><given-names>M</given-names></name></person-group>
<year>2015</year>
<article-title>ARTC1-mediated ADP-ribosylation of GRP78/BiP: a new player in endoplasmic-reticulum stress responses</article-title>. <source/>Cell Mol. Life Sci.
<volume>72</volume>, <fpage>1209</fpage>–<lpage>1225</lpage>. (<pub-id pub-id-type="doi">10.1007/s00018-014-1745-6</pub-id>)<pub-id pub-id-type="pmid">25292337</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martello</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Leutert</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jungmichel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bilan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Larsen</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hottiger</surname><given-names>MO</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>ML</given-names></name></person-group>
<year>2016</year>
<article-title>Proteome-wide identification of the endogenous ADP-ribosylome of mammalian cells and tissue</article-title>. <source/>Nat. Commun.
<volume>7</volume>, <fpage>12917</fpage> (<pub-id pub-id-type="doi">10.1038/ncomms12917</pub-id>)<pub-id pub-id-type="pmid">27686526</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leutert</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Proteomic characterization of the heart and skeletal muscle reveals widespread arginine ADP-ribosylation by the ARTC1 ectoenzyme</article-title>. <source/>Cell Rep.
<volume>24</volume>, <fpage>1916</fpage>–<lpage>1929</lpage>. (<pub-id pub-id-type="doi">10.1016/j.celrep.2018.07.048</pub-id>)<pub-id pub-id-type="pmid">30110646</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibson</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Kraus</surname><given-names>WL</given-names></name></person-group>
<year>2012</year>
<article-title>New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs</article-title>. <source/>Nat. Rev. Mol. Cell Biol.
<volume>13</volume>, <fpage>411</fpage>–<lpage>424</lpage>. (<pub-id pub-id-type="doi">10.1038/nrm3376</pub-id>)<pub-id pub-id-type="pmid">22713970</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leidecker</surname><given-names>O</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>Serine is a new target residue for endogenous ADP-ribosylation on histones</article-title>. <source/>Nat. Chem. Biol.
<volume>12</volume>, <fpage>998</fpage>–<lpage>1000</lpage>. (<pub-id pub-id-type="doi">10.1038/nchembio.2180</pub-id>)<pub-id pub-id-type="pmid">27723750</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crawford</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bonfiglio</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Mikoč</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Matic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2018</year>
<article-title>Specificity of reversible ADP-ribosylation and regulation of cellular processes</article-title>. <source/>Crit. Rev. Biochem. Mol. Biol.
<volume>53</volume>, <fpage>64</fpage>–<lpage>82</lpage>. (<pub-id pub-id-type="doi">10.1080/10409238.2017.1394265</pub-id>)<pub-id pub-id-type="pmid">29098880</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Murcia</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ménissier de Murcia</surname><given-names>J</given-names></name></person-group>
<year>1994</year>
<article-title>Poly(ADP-ribose) polymerase: a molecular nick-sensor</article-title>. <source/>Trends Biochem. Sci.
<volume>19</volume>, <fpage>172</fpage>–<lpage>176</lpage>. (<pub-id pub-id-type="doi">10.1016/0968-0004(94)90280-1</pub-id>)<pub-id pub-id-type="pmid">8016868</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Amours</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Desnoyers</surname><given-names>S</given-names></name>, <name name-style="western"><surname>D'Silva</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Poirier</surname><given-names>GG</given-names></name></person-group>
<year>1999</year>
<article-title>Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions</article-title>. <source/>Biochem. J.
<volume>342</volume>, <fpage>249</fpage>–<lpage>268</lpage>. (<pub-id pub-id-type="doi">10.1042/bj3420249</pub-id>)<pub-id pub-id-type="pmid">10455009</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rippmann</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Damm</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Schnapp</surname><given-names>A</given-names></name></person-group>
<year>2002</year>
<article-title>Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length</article-title>. <source/>J. Mol. Biol.
<volume>323</volume>, <fpage>217</fpage>–<lpage>224</lpage>. (<pub-id pub-id-type="doi">10.1016/S0022-2836(02)00946-4</pub-id>)<pub-id pub-id-type="pmid">12381316</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleine</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Poreba</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lesniewicz</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hassa</surname><given-names>PO</given-names></name>, <name name-style="western"><surname>Hottiger</surname><given-names>MO</given-names></name>, <name name-style="western"><surname>Litchfield</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Shilton</surname><given-names>BH</given-names></name>, <name name-style="western"><surname>Lüscher</surname><given-names>B</given-names></name></person-group>
<year>2008</year>
<article-title>Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation</article-title>. <source/>Mol. Cell.
<volume>32</volume>, <fpage>57</fpage>–<lpage>69</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2008.08.009</pub-id>)<pub-id pub-id-type="pmid">18851833</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bütepage</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Eckei</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Verheugd</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lüscher</surname><given-names>B</given-names></name></person-group>
<year>2015</year>
<article-title>Intracellular mono-ADP-ribosylation in signaling and disease</article-title>. <source/>Cells
<volume>4</volume>, <fpage>569</fpage>–<lpage>595</lpage>. (<pub-id pub-id-type="doi">10.3390/cells4040569</pub-id>)<pub-id pub-id-type="pmid">26426055</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berthold</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nordlund</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Högbom</surname><given-names>M</given-names></name></person-group>
<year>2009</year>
<article-title>Mechanism of ADP-ribosylation removal revealed by the structure and ligand complexes of the dimanganese mono-ADP-ribosylhydrolase DraG</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>106</volume>, <fpage>14 247</fpage>–<lpage>14 252</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0905906106</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oka</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kato</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>J</given-names></name></person-group>
<year>2006</year>
<article-title>Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase</article-title>. <source/>J. Biol. Chem.
<volume>281</volume>, <fpage>705</fpage>–<lpage>713</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M510290200</pub-id>)<pub-id pub-id-type="pmid">16278211</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rack</surname><given-names>JGM</given-names></name>, <name name-style="western"><surname>Ariza</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Drown</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Henfrey</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bartlett</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Shirai</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hergenrother</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2018</year>
<article-title>(ADP-ribosyl)hydrolases: structural basis for differential substrate recognition and inhibition</article-title>. <source/>Cell Chem. Biol.
<volume>25</volume>, <fpage>1533</fpage>–<lpage>1546</lpage>. (<pub-id pub-id-type="doi">10.1016/j.chembiol.2018.11.001</pub-id>)<pub-id pub-id-type="pmid">30472116</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Kato</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>J</given-names></name></person-group>
<year>2018</year>
<article-title>Emerging roles of ADP-ribosyl-acceptor hydrolases (ARHs) in tumorigenesis and cell death pathways</article-title>. <source/>Biochem. Pharmacol.
<volume>2952</volume>, <fpage>30 411</fpage>–<lpage>30 418</lpage>.</mixed-citation>
</ref>
<ref id="RSOB190041C65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kato</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Oda</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ishiwata-Endo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>J</given-names></name></person-group>
<year>2018</year>
<article-title>Enhanced sensitivity to cholera toxin in female ADP-ribosylarginine hydrolase (ARH1)-deficient mice</article-title>. <source/>PLoS ONE
<volume>13</volume>, <fpage>e0207693</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0207693</pub-id>)<pub-id pub-id-type="pmid">30500844</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fontana</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bonfiglio</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Palazzo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bartlett</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Matic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2017</year>
<article-title>Serine ADP-ribosylation reversal by the hydrolase ARH3</article-title>. <source/>Elife
<volume>6</volume>, <fpage>e28533</fpage> (<pub-id pub-id-type="doi">10.7554/eLife.28533</pub-id>)<pub-id pub-id-type="pmid">28650317</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C67">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drown</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Shirai</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Rack</surname><given-names>JGM</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hergenrother</surname><given-names>PJ</given-names></name></person-group>
<year>2018</year>
<article-title>Monitoring poly(ADP-ribosyl)glycohydrolase activity with a continuous fluorescent substrate</article-title>. <source/>Cell Chem. Biol.
<volume>25</volume>, <fpage>1562</fpage>–<lpage>1570</lpage>. (<pub-id pub-id-type="doi">10.1016/j.chembiol.2018.09.008</pub-id>)<pub-id pub-id-type="pmid">30318463</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feijs</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Forst</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Verheugd</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lüscher</surname><given-names>B</given-names></name></person-group>
<year>2013</year>
<article-title>Macrodomain-containing proteins: regulating new intracellular functions of mono(ADP-ribosyl)ation</article-title>. <source/>Nat. Rev. Mol. Cell Biol.
<volume>14</volume>, <fpage>443</fpage>–<lpage>451</lpage>. (<pub-id pub-id-type="doi">10.1038/nrm3601</pub-id>)<pub-id pub-id-type="pmid">23736681</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C69">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rack</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Perina</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2016</year>
<article-title>Macrodomains: structure, function, evolution, and catalytic activities</article-title>. <source/>Annu. Rev. Biochem.
<volume>85</volume>, <fpage>431</fpage>–<lpage>454</lpage>. (<pub-id pub-id-type="doi">10.1146/annurev-biochem-060815-014935</pub-id>)<pub-id pub-id-type="pmid">26844395</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karras</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kustatscher</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Buhecha</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Allen</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Pugieux</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sait</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bycroft</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ladurner</surname><given-names>AG</given-names></name></person-group>
<year>2005</year>
<article-title>The macro domain is an ADP-ribose binding module</article-title>. <source/>EMBO J.
<volume>24</volume>, <fpage>1911</fpage>–<lpage>1920</lpage>. (<pub-id pub-id-type="doi">10.1038/sj.emboj.7600664</pub-id>)<pub-id pub-id-type="pmid">15902274</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Denu</surname><given-names>JM</given-names></name></person-group>
<year>2010</year>
<article-title>Function and metabolism of sirtuin metabolite O-acetyl-ADP-ribose</article-title>. <source/>Biochim. Biophys. Acta
<volume>1804</volume>, <fpage>1617</fpage>–<lpage>1625</lpage>. (<pub-id pub-id-type="doi">10.1016/j.bbapap.2010.02.007</pub-id>)<pub-id pub-id-type="pmid">20176146</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neuvonen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ahola</surname><given-names>T</given-names></name></person-group>
<year>2009</year>
<article-title>Differential activities of cellular and viral macro domain proteins in binding of ADP-ribose metabolites</article-title>. <source/>J. Mol. Biol.
<volume>385</volume>, <fpage>212</fpage>–<lpage>225</lpage>. (<pub-id pub-id-type="doi">10.1016/j.jmb.2008.10.045</pub-id>)<pub-id pub-id-type="pmid">18983849</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slade</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Dunstan</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Barkauskaite</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Weston</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lafite</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dixon</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Leys</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2011</year>
<article-title>The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase</article-title>. <source/>Nature.
<volume>477</volume>, <fpage>616</fpage>–<lpage>620</lpage>. (<pub-id pub-id-type="doi">10.1038/nature10404</pub-id>)<pub-id pub-id-type="pmid">21892188</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jankevicius</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hassler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Golia</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rybin</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Zacharias</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Timinszky</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ladurner</surname><given-names>AG</given-names></name></person-group>
<year>2013</year>
<article-title>A family of macrodomain proteins reverses cellular mono-ADP-ribosylation</article-title>. <source/>Nat. Struct. Mol. Biol.
<volume>20</volume>, <fpage>508</fpage>–<lpage>514</lpage>. (<pub-id pub-id-type="doi">10.1038/nsmb.2523</pub-id>)<pub-id pub-id-type="pmid">23474712</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases</article-title>. <source/>Nat. Struct. Mol. Biol.
<volume>20</volume>, <fpage>502</fpage>–<lpage>507</lpage>. (<pub-id pub-id-type="doi">10.1038/nsmb.2521</pub-id>)<pub-id pub-id-type="pmid">23474714</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupte</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Kraus</surname><given-names>WL</given-names></name></person-group>
<year>2017</year>
<article-title>PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes</article-title>. <source/>Genes Dev.
<volume>31</volume>, <fpage>101</fpage>–<lpage>126</lpage>. (<pub-id pub-id-type="doi">10.1101/gad.291518.116</pub-id>)<pub-id pub-id-type="pmid">28202539</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langelier</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Eisemann</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Riccio</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Pascal</surname><given-names>JM</given-names></name></person-group>
<year>2018</year>
<article-title>PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification</article-title>. <source/>Curr. Opin. Struct. Biol.
<volume>53</volume>, <fpage>187</fpage>–<lpage>198</lpage>. (<pub-id pub-id-type="doi">10.1016/j.sbi.2018.11.002</pub-id>)<pub-id pub-id-type="pmid">30481609</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cantó</surname><given-names>C</given-names></name></person-group>
<year>2012</year>
<article-title>The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease</article-title>. <source/>Cell Metab.
<volume>16</volume>, <fpage>290</fpage>–<lpage>295</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cmet.2012.06.016</pub-id>)<pub-id pub-id-type="pmid">22921416</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Kraus</surname><given-names>WL</given-names></name></person-group>
<year>2012</year>
<article-title>On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1</article-title>. <source/>Genes Dev.
<volume>26</volume>, <fpage>417</fpage>–<lpage>432</lpage>. (<pub-id pub-id-type="doi">10.1101/gad.183509.111</pub-id>)<pub-id pub-id-type="pmid">22391446</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posavec</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Crawford</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2017</year>
<article-title>PARP, transcription and chromatin modeling</article-title>. <source/>Semin. Cell Dev. Biol.
<volume>63</volume>, <fpage>102</fpage>–<lpage>113</lpage>. (<pub-id pub-id-type="doi">10.1016/j.semcdb.2016.09.014</pub-id>)<pub-id pub-id-type="pmid">27677453</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Andrea</surname><given-names>AD</given-names></name></person-group>
<year>2018</year>
<article-title>Mechanisms of PARP inhibitor sensitivity and resistance</article-title>. <source/>DNA Repair (Amst).
<volume>71</volume>, <fpage>172</fpage>–<lpage>176</lpage>. (<pub-id pub-id-type="doi">10.1016/j.dnarep.2018.08.021</pub-id>)<pub-id pub-id-type="pmid">30177437</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pilié</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mills</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Yap</surname><given-names>TA</given-names></name></person-group>
<year>2019</year>
<article-title>State-of-the-art strategies for targeting the DNA damage response in cancer</article-title>. <source/>Nat. Rev. Clin. Oncol.
<volume>16</volume>, <fpage>81</fpage>–<lpage>104</lpage>. (<pub-id pub-id-type="doi">10.1038/s41571-018-0114-z</pub-id>)<pub-id pub-id-type="pmid">30356138</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C83">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibbs-Seymour</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Fontana</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Rack</surname><given-names>JGM</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2016</year>
<article-title>HPF1/C4orf27 Is a PARP-1-interacting protein that regulates PARP-1 ADP-ribosylation activity</article-title>. <source/>Mol. Cell
<volume>62</volume>, <fpage>432</fpage>–<lpage>442</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2016.03.008</pub-id>)<pub-id pub-id-type="pmid">27067600</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonfiglio</surname><given-names>JJ</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Serine ADP-ribosylation depends on HPF1</article-title>. <source/>Mol. Cell
<volume>65</volume>, <fpage>932</fpage>–<lpage>940</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2017.01.003</pub-id>)<pub-id pub-id-type="pmid">28190768</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palazzo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Leidecker</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Prokhorova</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Dauben</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Matic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2018</year>
<article-title>Serine is the major residue for ADP-ribosylation upon DNA damage</article-title>. <source/>Elife
<volume>7</volume>, <fpage>e34334</fpage> (<pub-id pub-id-type="doi">10.7554/eLife.34334</pub-id>)<pub-id pub-id-type="pmid">29480802</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Hendriks</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>Lyon</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>ML</given-names></name></person-group>
<year>2018</year>
<article-title>Systems-wide analysis of serine ADP-ribosylation reveals widespread occurrence and site-specific overlap with phosphorylation</article-title>. <source/>Cell. Rep.
<volume>24</volume>, <fpage>2493</fpage>–<lpage>2505</lpage>. (<pub-id pub-id-type="doi">10.1016/j.celrep.2018.07.083</pub-id>)<pub-id pub-id-type="pmid">30157440</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<year>2019</year>
<article-title>ELTA: enzymatic labeling of terminal ADP-ribose</article-title>. <source/>Mol. Cell.
<volume>73</volume>, <fpage>845</fpage>–<lpage>856</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2018.12.022</pub-id>)<pub-id pub-id-type="pmid">30712989</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartlett</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bonfiglio</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Prokhorova</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Colby</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zobel</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Matic</surname><given-names>I</given-names></name></person-group>
<year>2018</year>
<article-title>Interplay of histone marks with serine ADP-ribosylation</article-title>. <source/>Cell Rep.
<volume>24</volume>, <fpage>3488</fpage>–<lpage>3502</lpage>. (<pub-id pub-id-type="doi">10.1016/j.celrep.2018.08.092</pub-id>)<pub-id pub-id-type="pmid">30257210</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liszczak</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Diehl</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Dann</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Muir</surname><given-names>TW</given-names></name></person-group>
<year>2018</year>
<article-title>Acetylation blocks DNA damage-induced chromatin ADP-ribosylation</article-title>. <source/>Nat. Chem. Biol.
<volume>14</volume>, <fpage>837</fpage>–<lpage>840</lpage>. (<pub-id pub-id-type="doi">10.1038/s41589-018-0097-1</pub-id>)<pub-id pub-id-type="pmid">30013063</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eliasson</surname><given-names>MJ</given-names></name><etal>et al.</etal></person-group>
<year>1997</year>
<article-title>Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia</article-title>. <source/>Nat. Med.
<volume>3</volume>, <fpage>1089</fpage>–<lpage>1095</lpage>. (<pub-id pub-id-type="doi">10.1038/nm1097-1089</pub-id>)<pub-id pub-id-type="pmid">9334719</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiarugi</surname><given-names>A</given-names></name></person-group>
<year>2002</year>
<article-title>Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited</article-title>. <source/>Trends Pharmacol. Sci.
<volume>23</volume>, <fpage>122</fpage>–<lpage>129</lpage>. (<pub-id pub-id-type="doi">10.1016/S0165-6147(00)01902-7</pub-id>)<pub-id pub-id-type="pmid">11879679</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagtap</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Baloglu</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Southan</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Mabley</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>van Duzer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Salzman</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Szabó</surname><given-names>C</given-names></name></person-group>
<year>2005</year>
<article-title>Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone</article-title>. <source/>J. Med. Chem.
<volume>48</volume>, <fpage>5100</fpage>–<lpage>5103</lpage>. (<pub-id pub-id-type="doi">10.1021/jm0502891</pub-id>)<pub-id pub-id-type="pmid">16078828</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacher</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Szabo</surname><given-names>C</given-names></name></person-group>
<year>2008</year>
<article-title>Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease</article-title>. <source/>Am. J. Pathol.
<volume>173</volume>, <fpage>2</fpage>–<lpage>13</lpage>. (<pub-id pub-id-type="doi">10.2353/ajpath.2008.080019</pub-id>)<pub-id pub-id-type="pmid">18535182</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martire</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mosca</surname><given-names>L</given-names></name>, <name name-style="western"><surname>d'Erme</surname><given-names>M</given-names></name></person-group>
<year>2015</year>
<article-title>PARP-1 involvement in neurodegeneration: a focus on Alzheimer's and Parkinson's diseases</article-title>. <source/>Mech. Ageing Dev.
<volume>146–148</volume>, <fpage>53</fpage>–<lpage>64</lpage>. (<pub-id pub-id-type="doi">10.1016/j.mad.2015.04.001</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tóth-Zsámboki</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<year>2006</year>
<article-title>Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes</article-title>. <source/>Mol. Med.
<volume>12</volume>, <fpage>221</fpage>–<lpage>228</lpage>. (<pub-id pub-id-type="doi">10.2119/2006-00055.Toth-Zsamboki</pub-id>)<pub-id pub-id-type="pmid">17225870</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soriano</surname><given-names>FG</given-names></name><etal>et al.</etal></person-group>
<year>2006</year>
<article-title>Potential role of poly(adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock</article-title>. <source/>Crit. Care Med.
<volume>34</volume>, <fpage>1073</fpage>–<lpage>1079</lpage>. (<pub-id pub-id-type="doi">10.1097/01.CCM.0000206470.47721.8D</pub-id>)<pub-id pub-id-type="pmid">16484919</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>Y</given-names></name></person-group>
<year>2008</year>
<article-title>Acute myocardial infarction induced increases in plasma tumor necrosis factor-alpha and interleukin-10 are associated with the activation of poly(ADP-ribose) polymerase of circulating mononuclear cell</article-title>. <source/>Int. J. Cardiol.
<volume>123</volume>, <fpage>366</fpage>–<lpage>368</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ijcard.2007.06.069</pub-id>)<pub-id pub-id-type="pmid">17689746</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Love</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Barber</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wilcock</surname><given-names>GK</given-names></name></person-group>
<year>1999</year>
<article-title>Neuronal accumulation of poly(ADP-ribose) after brain ischaemia</article-title>. <source/>Neuropathol. Appl. Neurobiol.
<volume>25</volume>, <fpage>98</fpage>–<lpage>103</lpage>. (<pub-id pub-id-type="doi">10.1046/j.1365-2990.1999.00179.x</pub-id>)<pub-id pub-id-type="pmid">10215997</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Love</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Barber</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wilcock</surname><given-names>GK</given-names></name></person-group>
<year>2000</year>
<article-title>Neuronal death in brain infarcts in man</article-title>. <source/>Neuropathol. Appl. Neurobiol.
<volume>26</volume>, <fpage>55</fpage>–<lpage>66</lpage>. (<pub-id pub-id-type="doi">10.1046/j.1365-2990.2000.00218.x</pub-id>)<pub-id pub-id-type="pmid">10736067</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okolie</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Shall</surname><given-names>S</given-names></name></person-group>
<year>1979</year>
<article-title>The significance of antibodies to poly(adenosine diphosphate-ribose) in systemic lupus erythematosus</article-title>. <source/>Clin. Exp. Immunol.
<volume>36</volume>, <fpage>151</fpage>–<lpage>164</lpage>.<pub-id pub-id-type="pmid">313859</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negri</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<year>1990</year>
<article-title>Autoantibodies to poly(ADP-ribose)polymerase in autoimmune diseases</article-title>. <source/>Autoimmunity
<volume>6</volume>, <fpage>203</fpage>–<lpage>209</lpage>. (<pub-id pub-id-type="doi">10.3109/08916939009041040</pub-id>)<pub-id pub-id-type="pmid">2129778</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeoung</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>EB</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>YW</given-names></name></person-group>
<year>2004</year>
<article-title>Identification of autoantibody against poly (ADP-ribose) polymerase (PARP) fragment as a serological marker in systemic lupus erythematosus</article-title>. <source/>J. Autoimmun.
<volume>22</volume>, <fpage>87</fpage>–<lpage>94</lpage>. (<pub-id pub-id-type="doi">10.1016/j.jaut.2003.10.009</pub-id>)<pub-id pub-id-type="pmid">14709417</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reumaux</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mézière</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Colombel</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Duthilleul</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mueller</surname><given-names>S</given-names></name></person-group>
<year>1995</year>
<article-title>Distinct production of autoantibodies to nuclear components in ulcerative colitis and in Crohn's disease</article-title>. <source/>Clin. Immunol. Immunopathol.
<volume>77</volume>, <fpage>349</fpage>–<lpage>357</lpage>. (<pub-id pub-id-type="doi">10.1006/clin.1995.1162</pub-id>)<pub-id pub-id-type="pmid">7586746</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacher</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Szabó</surname><given-names>C</given-names></name></person-group>
<year>2005</year>
<article-title>Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme</article-title>. <source/>Antioxid. Redox Signal.
<volume>7</volume>, <fpage>1568</fpage>–<lpage>1580</lpage>. (<pub-id pub-id-type="doi">10.1089/ars.2005.7.1568</pub-id>)<pub-id pub-id-type="pmid">16356120</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacher</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Szabó</surname><given-names>C</given-names></name></person-group>
<year>2007</year>
<article-title>Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors</article-title>. <source/>Cardiovasc. Drug Rev.
<volume>25</volume>, <fpage>235</fpage>–<lpage>260</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1527-3466.2007.00018.x</pub-id>)<pub-id pub-id-type="pmid">17919258</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szabó</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zanchi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Komjáti</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pacher</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Krolewski</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Quist</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>LoGerfo</surname><given-names>FW</given-names></name>, <name name-style="western"><surname>Horton</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Veves</surname><given-names>A</given-names></name></person-group>
<year>2002</year>
<article-title>Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity</article-title>. <source/>Circulation
<volume>106</volume>, <fpage>2680</fpage>–<lpage>2686</lpage>. (<pub-id pub-id-type="doi">10.1161/01.CIR.0000038365.78031.9C</pub-id>)<pub-id pub-id-type="pmid">12438293</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinet</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Knaapen</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>De Meyer</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Herman</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Kockx</surname><given-names>MM</given-names></name></person-group>
<year>2002</year>
<article-title>Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques</article-title>. <source/>Circulation
<volume>106</volume>, <fpage>927</fpage>–<lpage>932</lpage>. (<pub-id pub-id-type="doi">10.1161/01.CIR.0000026393.47805.21</pub-id>)<pub-id pub-id-type="pmid">12186795</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adaikalakoteswari</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rema</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mohan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Balasubramanyam</surname><given-names>M</given-names></name></person-group>
<year>2007</year>
<article-title>Oxidative DNA damage and augmentation of poly(ADP-ribose) polymerase/nuclear factor-kappa B signaling in patients with type 2 diabetes and microangiopathy</article-title>. <source/>Int. J. Biochem. Cell Biol.
<volume>39</volume>, <fpage>1673</fpage>–<lpage>1684</lpage>. (<pub-id pub-id-type="doi">10.1016/j.biocel.2007.04.013</pub-id>)<pub-id pub-id-type="pmid">17540609</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C109">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoch</surname><given-names>NC</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia</article-title>. <source/>Nature
<volume>541</volume>, <fpage>87</fpage>–<lpage>91</lpage>. (<pub-id pub-id-type="doi">10.1038/nature20790</pub-id>)<pub-id pub-id-type="pmid">28002403</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C110">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kam</surname><given-names>TI</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease</article-title>. <source/>Science
<volume>362</volume>, <fpage>eaat8407</fpage> (<pub-id pub-id-type="doi">10.1126/science.aat8407</pub-id>)<pub-id pub-id-type="pmid">30385548</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C111">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Niedergang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Schreiber</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Muller</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Menissier-de Murcia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>de Murcia</surname><given-names>G</given-names></name></person-group>
<year>1998</year>
<article-title>XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage</article-title>. <source/>Mol. Cell Biol.
<volume>18</volume>, <fpage>3563</fpage>–<lpage>3571</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.18.6.3563</pub-id>)<pub-id pub-id-type="pmid">9584196</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C112">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Khamisy</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Masutani</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Caldecott</surname><given-names>KW</given-names></name></person-group>
<year>2003</year>
<article-title>A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage</article-title>. <source/>Nucleic Acids Res.
<volume>31</volume>, <fpage>5526</fpage>–<lpage>5533</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gkg761</pub-id>)<pub-id pub-id-type="pmid">14500814</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C113">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okano</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Caldecott</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>Mori</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yasui</surname><given-names>A</given-names></name></person-group>
<year>2003</year>
<article-title>Spatial and temporal cellular responses to single-strand breaks in human cells</article-title>. <source/>Mol. Cell Biol.
<volume>23</volume>, <fpage>3974</fpage>–<lpage>3981</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.23.11.3974-3981.2003</pub-id>)<pub-id pub-id-type="pmid">12748298</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C114">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Nakajima</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Oohata</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Takao</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Okano</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Masutani</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Yasui</surname><given-names>A</given-names></name></person-group>
<year>2004</year>
<article-title>In situ analysis of repair processes for oxidative DNA damage in mammalian cells</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>101</volume>, <fpage>13 738</fpage>–<lpage>13 743</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0406048101</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C115">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breslin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hornyak</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Rulten</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Hanzlikova</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Oliver</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Caldecott</surname><given-names>KW</given-names></name></person-group>
<year>2015</year>
<article-title>The XRCC1 phosphate-binding pocket binds poly (ADP-ribose) and is required for XRCC1 function</article-title>. <source/>Nucleic Acids Res.
<volume>43</volume>, <fpage>6934</fpage>–<lpage>6944</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gkv623</pub-id>)<pub-id pub-id-type="pmid">26130715</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C116">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreira</surname><given-names>MC</given-names></name><etal>et al.</etal></person-group>
<year>2001</year>
<article-title>The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin</article-title>. <source/>Nat. Genet.
<volume>29</volume>, <fpage>189</fpage>–<lpage>193</lpage>. (<pub-id pub-id-type="doi">10.1038/ng1001-189</pub-id>)<pub-id pub-id-type="pmid">11586300</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C117">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takashima</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<year>2002</year>
<article-title>Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy</article-title>. <source/>Nat. Genet.
<volume>32</volume>, <fpage>267</fpage>–<lpage>272</lpage>. (<pub-id pub-id-type="doi">10.1038/ng987</pub-id>)<pub-id pub-id-type="pmid">12244316</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C118">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Khamisy</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Saifi</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Weinfeld</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Johansson</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Helleday</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lupski</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Caldecott</surname><given-names>KW</given-names></name></person-group>
<year>2005</year>
<article-title>Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1</article-title>. <source/>Nature
<volume>434</volume>, <fpage>108</fpage>–<lpage>113</lpage>. (<pub-id pub-id-type="doi">10.1038/nature03314</pub-id>)<pub-id pub-id-type="pmid">15744309</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C119">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Rass</surname><given-names>U</given-names></name>, <name name-style="western"><surname>El-Khamisy</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Katyal</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Clements</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>McKinnon</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Caldecott</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>West</surname><given-names>SC</given-names></name></person-group>
<year>2006</year>
<article-title>The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates</article-title>. <source/>Nature
<volume>443</volume>, <fpage>713</fpage>–<lpage>716</lpage>. (<pub-id pub-id-type="doi">10.1038/nature05164</pub-id>)<pub-id pub-id-type="pmid">16964241</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C120">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rass</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>West</surname><given-names>SC</given-names></name></person-group>
<year>2007</year>
<article-title>Defective DNA repair and neurodegenerative disease</article-title>. <source/>Cell
<volume>130</volume>, <fpage>991</fpage>–<lpage>1004</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cell.2007.08.043</pub-id>)<pub-id pub-id-type="pmid">17889645</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C121">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bras</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Mutations in PNKP cause recessive ataxia with oculomotor apraxia type 4</article-title>. <source/>Am. J. Hum. Genet.
<volume>96</volume>, <fpage>474</fpage>–<lpage>479</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.01.005</pub-id>)<pub-id pub-id-type="pmid">25728773</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C122">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalia</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Kalia</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>McLean</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Lozano</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>AE</given-names></name></person-group>
<year>2013</year>
<article-title>α-Synuclein oligomers and clinical implications for Parkinson disease</article-title>. <source/>Ann. Neurol.
<volume>73</volume>, <fpage>155</fpage>–<lpage>169</lpage>. (<pub-id pub-id-type="doi">10.1002/ana.23746</pub-id>)<pub-id pub-id-type="pmid">23225525</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C123">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larson</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Lesné</surname><given-names>SE</given-names></name></person-group>
<year>2012</year>
<article-title>Soluble A<italic>β</italic> oligomer production and toxicity</article-title>. <source/>J. Neurochem.
<volume>120</volume>(<issue>Suppl. 1</issue>), <fpage>125</fpage>–<lpage>139</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07478.x</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C124">
<label>124</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tillement</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lecanu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Papadopoulos</surname><given-names>V</given-names></name></person-group>
<year>2011</year>
<article-title>Alzheimer's disease: effects of β-amyloid on mitochondria</article-title>. <source/>Mitochondrion
<volume>11</volume>, <fpage>13</fpage>–<lpage>21</lpage>. (<pub-id pub-id-type="doi">10.1016/j.mito.2010.08.009</pub-id>)<pub-id pub-id-type="pmid">20817045</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C125">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Son</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Byun</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mook-Jung</surname><given-names>I</given-names></name></person-group>
<year>2012</year>
<article-title>Mitochondria-specific accumulation of amyloid <italic>β</italic> induces mitochondrial dysfunction leading to apoptotic cell death</article-title>. <source/>PLoS ONE
<volume>7</volume>, <fpage>e34929</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0034929</pub-id>)<pub-id pub-id-type="pmid">22514691</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C126">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pithadia</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>MH</given-names></name></person-group>
<year>2012</year>
<article-title>Metal-associated amyloid-β species in Alzheimer's disease</article-title>. <source/>Curr. Opin. Chem. Biol.
<volume>16</volume>, <fpage>67</fpage>–<lpage>73</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cbpa.2012.01.016</pub-id>)<pub-id pub-id-type="pmid">22366383</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C127">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Ijaz</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Shabbiri</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Rehman</surname><given-names>S</given-names></name></person-group>
<year>2017</year>
<article-title>Oxidative toxicity in diabetes and Alzheimer's disease: mechanisms behind ROS/ RNS generation</article-title>. <source/>J. Biomed. Sci.
<volume>24</volume>, <fpage>76</fpage> (<pub-id pub-id-type="doi">10.1186/s12929-017-0379-z</pub-id>)<pub-id pub-id-type="pmid">28927401</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C128">
<label>128</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abeti</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Abramov</surname><given-names>AY</given-names></name>, <name name-style="western"><surname>Duchen</surname><given-names>MR</given-names></name></person-group>
<year>2011</year>
<article-title>Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death</article-title>. <source/>Brain
<volume>134</volume>, <fpage>1658</fpage>–<lpage>1672</lpage>. (<pub-id pub-id-type="doi">10.1093/brain/awr104</pub-id>)<pub-id pub-id-type="pmid">21616968</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C129">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelova</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Abramov</surname><given-names>AY</given-names></name></person-group>
<year>2014</year>
<article-title>Interaction of neurons and astrocytes underlies the mechanism of Aβ-induced neurotoxicity</article-title>. <source/>Biochem. Soc. Trans.
<volume>42</volume>, <fpage>1286</fpage>–<lpage>1290</lpage>. (<pub-id pub-id-type="doi">10.1042/BST20140153</pub-id>)<pub-id pub-id-type="pmid">25233405</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C130">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kauppinen</surname><given-names>TM</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid <italic>β</italic></article-title>. <source/>J. Neuroinflammation
<volume>8</volume>, <fpage>152</fpage> (<pub-id pub-id-type="doi">10.1186/1742-2094-8-152</pub-id>)<pub-id pub-id-type="pmid">22051244</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C131">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martire</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>PARP-1 modulates amyloid beta peptide-induced neuronal damage</article-title>. <source/>PLoS ONE
<volume>8</volume>, <fpage>e72169</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0072169</pub-id>)<pub-id pub-id-type="pmid">24086258</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C132">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackenzie</surname><given-names>IR</given-names></name><etal>et al.</etal></person-group>
<year>2007</year>
<article-title>Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations</article-title>. <source/>Ann. Neurol.
<volume>61</volume>, <fpage>427</fpage>–<lpage>434</lpage>. (<pub-id pub-id-type="doi">10.1002/ana.21147</pub-id>)<pub-id pub-id-type="pmid">17469116</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C133">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2008</year>
<article-title>Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis</article-title>. <source/>Ann. Neurol.
<volume>64</volume>, <fpage>60</fpage>–<lpage>70</lpage>. (<pub-id pub-id-type="doi">10.1002/ana.21425</pub-id>)<pub-id pub-id-type="pmid">18546284</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C134">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kedersha</surname><given-names>N</given-names></name></person-group>
<year>2008</year>
<article-title>Stress granules: the Tao of RNA triage</article-title>. <source/>Trends Biochem. Sci.
<volume>33</volume>, <fpage>141</fpage>–<lpage>150</lpage>. (<pub-id pub-id-type="doi">10.1016/j.tibs.2007.12.003</pub-id>)<pub-id pub-id-type="pmid">18291657</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C135">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>YR</given-names></name>, <name name-style="western"><surname>King</surname><given-names>OD</given-names></name>, <name name-style="western"><surname>Shorter</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gitler</surname><given-names>AD</given-names></name></person-group>
<year>2013</year>
<article-title>Stress granules as crucibles of ALS pathogenesis</article-title>. <source/>J. Cell Biol.
<volume>201</volume>, <fpage>361</fpage>–<lpage>372</lpage>. (<pub-id pub-id-type="doi">10.1083/jcb.201302044</pub-id>)<pub-id pub-id-type="pmid">23629963</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C136">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kedersha</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<year>2005</year>
<article-title>Stress granules and processing bodies are dynamically linked sites of mRNP remodeling</article-title>. <source/>J. Cell Biol.
<volume>169</volume>, <fpage>871</fpage>–<lpage>884</lpage>. (<pub-id pub-id-type="doi">10.1083/jcb.200502088</pub-id>)<pub-id pub-id-type="pmid">15967811</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C137">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Matthias</surname><given-names>P</given-names></name></person-group>
<year>2007</year>
<article-title>The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response</article-title>. <source/>Genes Dev.
<volume>21</volume>, <fpage>3381</fpage>–<lpage>3394</lpage>. (<pub-id pub-id-type="doi">10.1101/gad.461107</pub-id>)<pub-id pub-id-type="pmid">18079183</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C138">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Vyas</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rood</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bhutkar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sharp</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>P</given-names></name></person-group>
<year>2011</year>
<article-title>Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm</article-title>. <source/>Mol. Cell
<volume>42</volume>, <fpage>489</fpage>–<lpage>499</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2011.04.015</pub-id>)<pub-id pub-id-type="pmid">21596313</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C139">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bock</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Todorova</surname><given-names>TT</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>P</given-names></name></person-group>
<year>2015</year>
<article-title>RNA regulation by poly(adp-ribose) polymerases</article-title>. <source/>Mol. Cell
<volume>58</volume>, <fpage>959</fpage>–<lpage>969</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2015.01.037</pub-id>)<pub-id pub-id-type="pmid">26091344</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C140">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catara</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Grimaldi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schembri</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Spano</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Turacchio</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Lo Monte</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Beccari</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Valente</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Corda</surname><given-names>D</given-names></name></person-group>
<year>2017</year>
<article-title>PARP1-produced poly-ADP-ribose causes the PARP12 translocation to stress granules and impairment of Golgi complex functions</article-title>. <source/>Sci. Rep.
<volume>7</volume>, <fpage>14035</fpage> (<pub-id pub-id-type="doi">10.1038/s41598-017-14156-8</pub-id>)<pub-id pub-id-type="pmid">29070863</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C141">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGurk</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis</article-title>. <source/>Acta Neuropathol. Commun.
<volume>6</volume>, <fpage>84</fpage> (<pub-id pub-id-type="doi">10.1186/s40478-018-0586-1</pub-id>)<pub-id pub-id-type="pmid">30157956</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C142">
<label>142</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGurk</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gomes</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mojsilovic-Petrovic</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tran</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Kalb</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Shorter</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bonini</surname><given-names>NM</given-names></name></person-group>
<year>2018</year>
<article-title>Poly(ADP-ribose) prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization</article-title>. <source/>Mol. Cell
<volume>71</volume>, <fpage>703</fpage>–<lpage>717</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2018.07.002</pub-id>)<pub-id pub-id-type="pmid">30100264</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C143">
<label>143</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danese</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fiocchi</surname><given-names>C</given-names></name></person-group>
<year>2011</year>
<article-title>Ulcerative colitis</article-title>. <source/>N. Engl. J. Med.
<volume>365</volume>, <fpage>1713</fpage>–<lpage>1725</lpage>. (<pub-id pub-id-type="doi">10.1056/NEJMra1102942</pub-id>)<pub-id pub-id-type="pmid">22047562</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C144">
<label>144</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Kanazawa</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shih</surname><given-names>DQ</given-names></name></person-group>
<year>2014</year>
<article-title>Immunopathology of inflammatory bowel disease</article-title>. <source/>World J. Gastroenterol.
<volume>20</volume>, <fpage>6</fpage>–<lpage>21</lpage>. (<pub-id pub-id-type="doi">10.3748/wjg.v20.i1.6</pub-id>)<pub-id pub-id-type="pmid">24415853</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C145">
<label>145</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ungaro</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mehandru</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Allen</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Peyrin-Biroulet</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Colombel</surname><given-names>JF</given-names></name></person-group>
<year>2017</year>
<article-title>Ulcerative colitis</article-title>. <source/>Lancet
<volume>389</volume>, <fpage>1756</fpage>–<lpage>1770</lpage>. (<pub-id pub-id-type="doi">10.1016/S0140-6736(16)32126-2</pub-id>)<pub-id pub-id-type="pmid">27914657</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C146">
<label>146</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>OJ</given-names></name>, <name name-style="western"><surname>Maloy</surname><given-names>KJ</given-names></name></person-group>
<year>2011</year>
<article-title>Innate immune activation in intestinal homeostasis</article-title>. <source/>J. Innate Immun<italic>.</italic>
<volume>3</volume>, <fpage>585</fpage>–<lpage>593</lpage>. (<pub-id pub-id-type="doi">10.1159/000330913</pub-id>)<pub-id pub-id-type="pmid">21912101</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C147">
<label>147</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei-Leston</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Maloy</surname><given-names>KJ</given-names></name></person-group>
<year>2017</year>
<article-title>Epithelial cell inflammasomes in intestinal immunity and inflammation</article-title>. <source/>Front. Immunol.
<volume>8</volume>, <fpage>1168</fpage> (<pub-id pub-id-type="doi">10.3389/fimmu.2017.01168</pub-id>)<pub-id pub-id-type="pmid">28979266</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C148">
<label>148</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogler</surname><given-names>G</given-names></name></person-group>
<year>2014</year>
<article-title>Chronic ulcerative colitis and colorectal cancer</article-title>. <source/>Cancer Lett.
<volume>345</volume>, <fpage>235</fpage>–<lpage>241</lpage>. (<pub-id pub-id-type="doi">10.1016/j.canlet.2013.07.032</pub-id>)<pub-id pub-id-type="pmid">23941831</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C149">
<label>149</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Der Kraak</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gros</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Beauchemin</surname><given-names>N</given-names></name></person-group>
<year>2015</year>
<article-title>Colitis-associated colon cancer: is it in your genes?</article-title>
<source/>World J. Gastroenterol.
<volume>21</volume>, <fpage>11 688</fpage>–<lpage>11 699</lpage>. (<pub-id pub-id-type="doi">10.3748/wjg.v21.i41.11688</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C150">
<label>150</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Bakir</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Curtius</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>TA</given-names></name></person-group>
<year>2018</year>
<article-title>From colitis to cancer: an evolutionary trajectory that merges maths and biology</article-title>. <source/>Front. Immunol.
<volume>9</volume>, <fpage>2368</fpage> (<pub-id pub-id-type="doi">10.3389/fimmu.2018.02368</pub-id>)<pub-id pub-id-type="pmid">30386335</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C151">
<label>151</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dörsam</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>115</volume>, <fpage>E4061</fpage>–<lpage>E4070</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.1712345115</pub-id>)<pub-id pub-id-type="pmid">29632181</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C152">
<label>152</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Manis</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shipp</surname><given-names>MA</given-names></name></person-group>
<year>2013</year>
<article-title>BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8</article-title>. <source/>Mol. Cell Biol.
<volume>33</volume>, <fpage>845</fpage>–<lpage>857</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.00990-12</pub-id>)<pub-id pub-id-type="pmid">23230272</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C153">
<label>153</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>CS</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Ubiquitin modification by the E3 ligase/ADP-ribosyltransferase Dtx3 L/Parp9</article-title>. <source/>Mol Cell.
<volume>66</volume>, <fpage>503</fpage>–<lpage>516</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2017.04.028</pub-id>)<pub-id pub-id-type="pmid">28525742</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C154">
<label>154</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juszczynski</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kutok</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mitra</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Aguiar</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Shipp</surname><given-names>MA</given-names></name></person-group>
<year>2006</year>
<article-title>BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate</article-title>. <source/>Mol. Cell Biol.
<volume>26</volume>, <fpage>5348</fpage>–<lpage>5359</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.02351-05</pub-id>)<pub-id pub-id-type="pmid">16809771</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C155">
<label>155</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camicia</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bachmann</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Winkler</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Beer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tinguely</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haralambieva</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hassa</surname><given-names>PO</given-names></name></person-group>
<year>2013</year>
<article-title>BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma</article-title>. <source/>J. Cell Sci.
<volume>126</volume>, <fpage>1969</fpage>–<lpage>1980</lpage>. (<pub-id pub-id-type="doi">10.1242/jcs.118174</pub-id>)<pub-id pub-id-type="pmid">23487038</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C156">
<label>156</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goenka</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Boothby</surname><given-names>M</given-names></name></person-group>
<year>2006</year>
<article-title>Selective potentiation of Stat-dependent gene expression by collaborator of Stat6 (CoaSt6), a transcriptional cofactor</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>103</volume>, <fpage>4210</fpage>–<lpage>4215</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0506981103</pub-id>)<pub-id pub-id-type="pmid">16537510</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C157">
<label>157</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goenka</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Boothby</surname><given-names>M</given-names></name></person-group>
<year>2007</year>
<article-title>Collaborator of Stat6 (CoaSt6)-associated poly(ADP-ribose) polymerase activity modulates Stat6-dependent gene transcription</article-title>. <source/>J. Biol. Chem.
<volume>282</volume>, <fpage>18 732</fpage>–<lpage>18 739</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M611283200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C158">
<label>158</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehrotra</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hollenbeck</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Riley</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Akhtar</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Goenka</surname><given-names>S</given-names></name></person-group>
<year>2013</year>
<article-title>Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease</article-title>. <source/>J. Allergy Clin. Immunol.
<volume>131</volume>, <fpage>521</fpage>–<lpage>531</lpage>. (<pub-id pub-id-type="doi">10.1016/j.jaci.2012.06.015</pub-id>)<pub-id pub-id-type="pmid">22841009</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C159">
<label>159</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>A</given-names></name></person-group>
<year>2000</year>
<article-title>Th1 and Th2 responses: what are they?</article-title>
<source/>Br. Med. J.
<volume>321</volume>, <fpage>424</fpage> (<pub-id pub-id-type="doi">10.1136/bmj.321.7258.424</pub-id>)<pub-id pub-id-type="pmid">10938051</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C160">
<label>160</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Ahn</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Bhargava</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Eischen</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>McGuinness</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Boothby</surname><given-names>M</given-names></name></person-group>
<year>2011</year>
<article-title>Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>108</volume>, <fpage>15 972</fpage>–<lpage>15 977</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.1017082108</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C161">
<label>161</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Takehana</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Date</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shinozaki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Raz</surname><given-names>A</given-names></name></person-group>
<year>1996</year>
<article-title>Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide</article-title>. <source/>Cancer Res.
<volume>56</volume>, <fpage>2960</fpage>–<lpage>2963</lpage>.<pub-id pub-id-type="pmid">8674049</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C162">
<label>162</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funasaka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Haga</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Raz</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nagase</surname><given-names>H</given-names></name></person-group>
<year>2001</year>
<article-title>Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>285</volume>, <fpage>118</fpage>–<lpage>128</lpage>. (<pub-id pub-id-type="doi">10.1006/bbrc.2001.5135</pub-id>)<pub-id pub-id-type="pmid">11437381</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C163">
<label>163</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funasaka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Haga</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Raz</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nagase</surname><given-names>H</given-names></name></person-group>
<year>2002</year>
<article-title>Tumor autocrine motility factor induces hyperpermeability of endothelial and mesothelial cells leading to accumulation of ascites fluid</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>293</volume>, <fpage>192</fpage>–<lpage>200</lpage>. (<pub-id pub-id-type="doi">10.1016/S0006-291X(02)00202-4</pub-id>)<pub-id pub-id-type="pmid">12054583</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C164">
<label>164</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forst</surname><given-names>AH</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Recognition of mono-ADP-ribosylated ARTD10 substrates by ARTD8 macrodomains</article-title>. <source/>Structure
<volume>21</volume>, <fpage>462</fpage>–<lpage>475</lpage>. (<pub-id pub-id-type="doi">10.1016/j.str.2012.12.019</pub-id>)<pub-id pub-id-type="pmid">23473667</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C165">
<label>165</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Giriat</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Schmitt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>de Lange</surname><given-names>T</given-names></name></person-group>
<year>1998</year>
<article-title>Tankyrase, a poly(ADP-ribose) polymerase at human telomeres</article-title>. <source/>Science
<volume>282</volume>, <fpage>1484</fpage>–<lpage>1487</lpage>. (<pub-id pub-id-type="doi">10.1126/science.282.5393.1484</pub-id>)<pub-id pub-id-type="pmid">9822378</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C166">
<label>166</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>S</given-names></name>, <name name-style="western"><surname>de Lange</surname><given-names>T</given-names></name></person-group>
<year>1999</year>
<article-title>Cell cycle dependent localization of the telomeric PARP, tankyrase, to nuclear pore complexes and centrosomes</article-title>. <source/>J. Cell Sci.
<volume>112</volume>, <fpage>3649</fpage>–<lpage>3656</lpage>.<pub-id pub-id-type="pmid">10523501</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C167">
<label>167</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dynek</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>S</given-names></name></person-group>
<year>2004</year>
<article-title>Resolution of sister telomere association is required for progression through mitosis</article-title>. <source/>Science
<volume>304</volume>, <fpage>97</fpage>–<lpage>100</lpage>. (<pub-id pub-id-type="doi">10.1126/science.1094754</pub-id>)<pub-id pub-id-type="pmid">15064417</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C168">
<label>168</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Coughlin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mitchison</surname><given-names>TJ</given-names></name></person-group>
<year>2005</year>
<article-title>Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function</article-title>. <source/>Nat. Cell Biol.
<volume>7</volume>, <fpage>1133</fpage>–<lpage>1139</lpage>. (<pub-id pub-id-type="doi">10.1038/ncb1322</pub-id>)<pub-id pub-id-type="pmid">16244666</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C169">
<label>169</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>S</given-names></name></person-group>
<year>2008</year>
<article-title>Tankyrase function at telomeres, spindle poles, and beyond</article-title>. <source/>Biochimie
<volume>90</volume>, <fpage>83</fpage>–<lpage>92</lpage>. (<pub-id pub-id-type="doi">10.1016/j.biochi.2007.07.012</pub-id>)<pub-id pub-id-type="pmid">17825467</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C170">
<label>170</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>SM</given-names></name><etal>et al.</etal></person-group>
<year>2009</year>
<article-title>Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling</article-title>. <source/>Nature
<volume>461</volume>, <fpage>614</fpage>–<lpage>620</lpage>. (<pub-id pub-id-type="doi">10.1038/nature08356</pub-id>)<pub-id pub-id-type="pmid">19759537</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C171">
<label>171</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palazzo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Della Monica</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Visconti</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Costanzo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Grieco</surname><given-names>D</given-names></name></person-group>
<year>2014</year>
<article-title>ATM controls proper mitotic spindle structure</article-title>. <source/>Cell Cycle
<volume>13</volume>, <fpage>1091</fpage>–<lpage>1100</lpage>. (<pub-id pub-id-type="doi">10.4161/cc.27945</pub-id>)<pub-id pub-id-type="pmid">24553124</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C172">
<label>172</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagy</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Kalousi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Furst</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koch</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Soutoglou</surname><given-names>E</given-names></name></person-group>
<year>2016</year>
<article-title>Tankyrases promote homologous recombination and check point activation in response to DSBs</article-title>. <source/>PLoS Genet.
<volume>12</volume>, <fpage>e1005791</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pgen.1005791</pub-id>)<pub-id pub-id-type="pmid">26845027</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C173">
<label>173</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhardwaj</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ueberheide</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>S</given-names></name></person-group>
<year>2017</year>
<article-title>Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation</article-title>. <source/>Nat. Commun.
<volume>8</volume>, <fpage>2214</fpage> (<pub-id pub-id-type="doi">10.1038/s41467-017-02363-w</pub-id>)<pub-id pub-id-type="pmid">29263426</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C174">
<label>174</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ta</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W</given-names></name></person-group>
<year>2017</year>
<article-title>Proteomic analysis of the human tankyrase protein interaction network reveals its role in pexophagy</article-title>. <source/>Cell Rep.
<volume>20</volume>, <fpage>737</fpage>–<lpage>749</lpage>. (<pub-id pub-id-type="doi">10.1016/j.celrep.2017.06.077</pub-id>)<pub-id pub-id-type="pmid">28723574</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C175">
<label>175</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guettler</surname><given-names>S</given-names></name>, <name name-style="western"><surname>LaRose</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Petsalaki</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gish</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Scotter</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pawson</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Rottapel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sicheri</surname><given-names>F</given-names></name></person-group>
<year>2011</year>
<article-title>Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease</article-title>. <source/>Cell
<volume>147</volume>, <fpage>1340</fpage>–<lpage>1354</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cell.2011.10.046</pub-id>)<pub-id pub-id-type="pmid">22153077</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C176">
<label>176</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sbodio</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Chi</surname><given-names>NW</given-names></name></person-group>
<year>2002</year>
<article-title>Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1. NuMA contains this RXXPDG motif and is a novel tankyrase partner</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>31 887</fpage>–<lpage>31 892</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M203916200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C177">
<label>177</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling</article-title>. <source/>Nat Cell Biol.
<volume>13</volume>, <fpage>623</fpage>–<lpage>629</lpage>. (<pub-id pub-id-type="doi">10.1038/ncb2222</pub-id>)<pub-id pub-id-type="pmid">21478859</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C178">
<label>178</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth</article-title>. <source/>Genes Dev.
<volume>29</volume>, <fpage>157</fpage>–<lpage>170</lpage>. (<pub-id pub-id-type="doi">10.1101/gad.251785.114</pub-id>)<pub-id pub-id-type="pmid">25547115</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C179">
<label>179</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Tran</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group>
<year>2015</year>
<article-title>Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins</article-title>. <source/>Cell Rep.
<volume>13</volume>, <fpage>524</fpage>–<lpage>532</lpage>. (<pub-id pub-id-type="doi">10.1016/j.celrep.2015.09.014</pub-id>)<pub-id pub-id-type="pmid">26456820</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C180">
<label>180</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krastev</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Pettitt</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Tanos</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Stoynov</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Ashworth</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lord</surname><given-names>CJ</given-names></name></person-group>
<year>2018</year>
<article-title>Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets</article-title>. <source/>Nat. Commun.
<volume>9</volume>, <fpage>2016</fpage> (<pub-id pub-id-type="doi">10.1038/s41467-018-04466-4</pub-id>)<pub-id pub-id-type="pmid">29789535</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C181">
<label>181</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riffell</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Lord</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Ashworth</surname><given-names>A</given-names></name></person-group>
<year>2012</year>
<article-title>Tankyrase-targeted therapeutics: expanding opportunities in the PARP family</article-title>. <source/>Nat. Rev. Drug Discov.
<volume>11</volume>, <fpage>923</fpage>–<lpage>936</lpage>. (<pub-id pub-id-type="doi">10.1038/nrd3868</pub-id>)<pub-id pub-id-type="pmid">23197039</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C182">
<label>182</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chi</surname><given-names>NW</given-names></name>, <name name-style="western"><surname>Lodish</surname><given-names>HF</given-names></name></person-group>
<year>2000</year>
<article-title>Tankyrase is a golgi-associated mitogen-activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles</article-title>. <source/>J. Biol. Chem.
<volume>275</volume>, <fpage>38 437</fpage>–<lpage>38 444</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M007635200</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C183">
<label>183</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>TY</given-names></name>, <name name-style="western"><surname>Beiswenger</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bolin</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Tsao</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Hevener</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Chi</surname><given-names>NW</given-names></name></person-group>
<year>2009</year>
<article-title>Hypermetabolism, hyperphagia, and reduced adiposity in tankyrase-deficient mice</article-title>. <source/>Diabetes
<volume>58</volume>, <fpage>2476</fpage>–<lpage>2485</lpage>. (<pub-id pub-id-type="doi">10.2337/db08-1781</pub-id>)<pub-id pub-id-type="pmid">19651815</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C184">
<label>184</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>HL</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>The Axin/TNKS complex interacts with KIF3A and is required for insulin-stimulated GLUT4 translocation</article-title>. <source/>Cell Res.
<volume>22</volume>, <fpage>1246</fpage>–<lpage>1257</lpage>. (<pub-id pub-id-type="doi">10.1038/cr.2012.52</pub-id>)<pub-id pub-id-type="pmid">22473005</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C185">
<label>185</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Deshpande</surname><given-names>V</given-names></name>, <name name-style="western"><surname>James</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Stöckli</surname><given-names>J</given-names></name></person-group>
<year>2018</year>
<article-title>Tankyrase modulates insulin sensitivity in skeletal muscle cells by regulating the stability of GLUT4 vesicle proteins</article-title>. <source/>J. Biol. Chem.
<volume>293</volume>, <fpage>8578</fpage>–<lpage>8587</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.RA117.001058</pub-id>)<pub-id pub-id-type="pmid">29669812</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C186">
<label>186</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizutani</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model</article-title>. <source/>Cancer Sci.
<volume>109</volume>, <fpage>4003</fpage>–<lpage>4014</lpage>. (<pub-id pub-id-type="doi">10.1111/cas.13805</pub-id>)<pub-id pub-id-type="pmid">30238564</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C187">
<label>187</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fancy</surname><given-names>SP</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination</article-title>. <source/>Nat. Neurosci.
<volume>14</volume>, <fpage>1009</fpage>–<lpage>1016</lpage>. (<pub-id pub-id-type="doi">10.1038/nn.2855</pub-id>)<pub-id pub-id-type="pmid">21706018</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C188">
<label>188</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Gerrie</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pritchard</surname><given-names>J</given-names></name></person-group>
<year>1950</year>
<article-title>Cherubism--familial fibrous dysplasia of the jaws</article-title>. <source/>J. Bone Joint Surg. Br.
<volume>32-B</volume>, <fpage>334</fpage>–<lpage>347</lpage>. (<pub-id pub-id-type="doi">10.1302/0301-620X.32B3.334</pub-id>)<pub-id pub-id-type="pmid">14778852</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C189">
<label>189</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueki</surname><given-names>Y</given-names></name><etal>et al.</etal></person-group>
<year>2001</year>
<article-title>Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism</article-title>. <source/>Nat. Genet.
<volume>28</volume>, <fpage>125</fpage>–<lpage>126</lpage>. (<pub-id pub-id-type="doi">10.1038/88832</pub-id>)<pub-id pub-id-type="pmid">11381256</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C190">
<label>190</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levaot</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism</article-title>. <source/>Cell
<volume>147</volume>, <fpage>1324</fpage>–<lpage>1339</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cell.2011.10.045</pub-id>)<pub-id pub-id-type="pmid">22153076</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C191">
<label>191</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perina</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mikoč</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ćetković</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Žaja</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2014</year>
<article-title>Distribution of protein poly(ADP-ribosyl)ation systems across all domains of life</article-title>. <source/>DNA Repair (Amst).
<volume>23</volume>, <fpage>4</fpage>–<lpage>16</lpage>. (<pub-id pub-id-type="doi">10.1016/j.dnarep.2014.05.003</pub-id>)<pub-id pub-id-type="pmid">24865146</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C192">
<label>192</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>Identification of macrodomain proteins as novel O-acetyl-ADP-ribose deacetylases</article-title>. <source/>J. Biol. Chem.
<volume>286</volume>, <fpage>13 261</fpage>–<lpage>13 271</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M110.206771</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C193">
<label>193</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>ZQ</given-names></name>, <name name-style="western"><surname>Si</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>YG</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>XB</given-names></name>, <name name-style="western"><surname>Mu</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>WD</given-names></name></person-group>
<year>2009</year>
<article-title>The single-macro domain protein LRP16 is an essential cofactor of androgen receptor</article-title>. <source/>Endocr. Relat. Cancer
<volume>16</volume>, <fpage>139</fpage>–<lpage>153</lpage>. (<pub-id pub-id-type="doi">10.1677/ERC-08-0150</pub-id>)<pub-id pub-id-type="pmid">19022849</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C194">
<label>194</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>An LRP16-containing preassembly complex contributes to NF-κB activation induced by DNA double-strand breaks</article-title>. <source/>Nucleic Acids Res.
<volume>43</volume>, <fpage>3167</fpage>–<lpage>3179</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gkv161</pub-id>)<pub-id pub-id-type="pmid">25735744</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C195">
<label>195</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><etal>et al.</etal></person-group>
<year>2011</year>
<article-title>LRP16 integrates into NF-κB transcriptional complex and is required for its functional activation</article-title>. <source/>PLoS ONE
<volume>6</volume>, <fpage>e18157</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0018157</pub-id>)<pub-id pub-id-type="pmid">21483817</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C196">
<label>196</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agnew</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Munnur</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Crawford</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Palazzo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mikoč</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2018</year>
<article-title>MacroD1 is a promiscuous ADP-ribosyl hydrolase localized to mitochondria</article-title>. <source/>Front. Microbiol.
<volume>9</volume>, <fpage>20</fpage> (<pub-id pub-id-type="doi">10.3389/fmicb.2018.00020</pub-id>)<pub-id pub-id-type="pmid">29410655</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C197">
<label>197</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verheugd</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Forst</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Milke</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Herzog</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Feijs</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Kremmer</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kleine</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Lüscher</surname><given-names>B</given-names></name></person-group>
<year>2013</year>
<article-title>Regulation of NF-κB signalling by the mono-ADP-ribosyltransferase ARTD10</article-title>. <source/>Nat. Commun.
<volume>4</volume>, <fpage>1683</fpage> (<pub-id pub-id-type="doi">10.1038/ncomms2672</pub-id>)<pub-id pub-id-type="pmid">23575687</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C198">
<label>198</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feijs</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Kleine</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Braczynski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Forst</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Herzog</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Verheugd</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Linzen</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Kremmer</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lüscher</surname><given-names>B</given-names></name></person-group>
<year>2013</year>
<article-title>ARTD10 substrate identification on protein microarrays: regulation of GSK3<italic>β</italic> by mono-ADP-ribosylation</article-title>. <source/>Cell Commun. Signal.
<volume>11</volume>, <fpage>5</fpage> (<pub-id pub-id-type="doi">10.1186/1478-811X-11-5</pub-id>)<pub-id pub-id-type="pmid">23332125</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C199">
<label>199</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folstein</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rutter</surname><given-names>M</given-names></name></person-group>
<year>1977</year>
<article-title>Infantile autism: a genetic study of 21 twin pairs</article-title>. <source/>J. Child Psychol. Psychiatry
<volume>18</volume>, <fpage>297</fpage>–<lpage>321</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1469-7610.1977.tb00443.x</pub-id>)<pub-id pub-id-type="pmid">562353</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C200">
<label>200</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritvo</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Freeman</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Mason-Brothers</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ritvo</surname><given-names>AM</given-names></name></person-group>
<year>1985</year>
<article-title>Concordance for the syndrome of autism in 40 pairs of afflicted twins</article-title>. <source/>Am. J. Psychiatry
<volume>142</volume>, <fpage>74</fpage>–<lpage>77</lpage>. (<pub-id pub-id-type="doi">10.1176/ajp.142.1.74</pub-id>)<pub-id pub-id-type="pmid">4038442</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C201">
<label>201</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miles</surname><given-names>JH</given-names></name></person-group>
<year>2011</year>
<article-title>Autism spectrum disorders—a genetics review</article-title>. <source/>Genet. Med.
<volume>13</volume>, <fpage>278</fpage>–<lpage>294</lpage>. (<pub-id pub-id-type="doi">10.1097/GIM.0b013e3181ff67ba</pub-id>)<pub-id pub-id-type="pmid">21358411</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C202">
<label>202</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wessels</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Brooks</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Hoogeboom</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Niermeijer</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Willems</surname><given-names>PJ</given-names></name></person-group>
<year>2002</year>
<article-title>Kabuki syndrome: a review study of three hundred patients</article-title>. <source/>Clin. Dysmorphol.
<volume>11</volume>, <fpage>95</fpage>–<lpage>102</lpage>. (<pub-id pub-id-type="doi">10.1097/00019605-200204000-00004</pub-id>)<pub-id pub-id-type="pmid">12002156</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C203">
<label>203</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lintas</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Persico</surname><given-names>AM</given-names></name></person-group>
<year>2018</year>
<article-title>Unraveling molecular pathways shared by Kabuki and Kabuki-like syndromes</article-title>. <source/>Clin. Genet.
<volume>94</volume>, <fpage>283</fpage>–<lpage>295</lpage>. (<pub-id pub-id-type="doi">10.1111/cge.12983</pub-id>)<pub-id pub-id-type="pmid">28139835</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C204">
<label>204</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>FC</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lytle</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Rossi</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Denu</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Volkman</surname><given-names>BF</given-names></name></person-group>
<year>2011</year>
<article-title>Orphan macrodomain protein (human C6orf130) is an O-acyl-ADP-ribose deacylase: solution structure and catalytic properties</article-title>. <source/>J. Biol. Chem.
<volume>286</volume>, <fpage>35 955</fpage>–<lpage>35 965</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M111.276238</pub-id>)<pub-id pub-id-type="pmid">21051542</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C205">
<label>205</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munnur</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2017</year>
<article-title>Reversible mono-ADP-ribosylation of DNA breaks</article-title>. <source/>FEBS J.
<volume>284</volume>, <fpage>4002</fpage>–<lpage>4016</lpage>. (<pub-id pub-id-type="doi">10.1111/febs.14297</pub-id>)<pub-id pub-id-type="pmid">29054115</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C206">
<label>206</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Chambers</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Liehr</surname><given-names>JG</given-names></name></person-group>
<year>1984</year>
<article-title>Glutamyl ribose 5-phosphate storage disease: a hereditary defect in the degradation of poly(ADP-ribosylated) proteins</article-title>. <source/>J. Biol. Chem.
<volume>259</volume>, <fpage>1037</fpage>–<lpage>1042</lpage>.<pub-id pub-id-type="pmid">6693374</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C207">
<label>207</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Verani</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Alcala</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Butler</surname><given-names>IJ</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>HS</given-names></name></person-group>
<year>1986</year>
<article-title>Glutamyl ribose-5-phosphate storage disease: nephrotic syndrome and cerebral atrophy</article-title>. <source/>Pediatr. Pathol.
<volume>5</volume>, <fpage>277</fpage>–<lpage>294</lpage>. (<pub-id pub-id-type="doi">10.3109/15513818609068855</pub-id>)<pub-id pub-id-type="pmid">3786260</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C208">
<label>208</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palazzo</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Processing of protein ADP-ribosylation by Nudix hydrolases</article-title>. <source/>Biochem. J.
<volume>468</volume>, <fpage>293</fpage>–<lpage>301</lpage>. (<pub-id pub-id-type="doi">10.1042/BJ20141554</pub-id>)<pub-id pub-id-type="pmid">25789582</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C209">
<label>209</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Thirawatananond</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ong</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gabelli</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>AK</given-names></name></person-group>
<year>2015</year>
<article-title>Nudix hydrolases degrade protein-conjugated ADP-ribose</article-title>. <source/>Sci. Rep.
<volume>5</volume>, <fpage>18271</fpage> (<pub-id pub-id-type="doi">10.1038/srep18271</pub-id>)<pub-id pub-id-type="pmid">26669448</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C210">
<label>210</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palazzo</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>ENPP1 processes protein ADP-ribosylation in vitro</article-title>. <source/>FEBS J.
<volume>283</volume>, <fpage>3371</fpage>–<lpage>3388</lpage>. (<pub-id pub-id-type="doi">10.1111/febs.13811</pub-id>)<pub-id pub-id-type="pmid">27406238</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C211">
<label>211</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunstan</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Barkauskaite</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lafite</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Knezevic</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Brassington</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hergenrother</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Leys</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2012</year>
<article-title>Structure and mechanism of a canonical poly(ADP-ribose) glycohydrolase</article-title>. <source/>Nat. Commun.
<volume>3</volume>, <fpage>878</fpage> (<pub-id pub-id-type="doi">10.1038/ncomms1889</pub-id>)<pub-id pub-id-type="pmid">22673905</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C212">
<label>212</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>IK</given-names></name>, <name name-style="western"><surname>Kiefer</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Stegeman</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Classen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tainer</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Ellenberger</surname><given-names>T</given-names></name></person-group>
<year>2012</year>
<article-title>Structure of mammalian poly(ADP-ribose) glycohydrolase reveals a flexible tyrosine clasp as a substrate-binding element</article-title>. <source/>Nat. Struct. Mol. Biol.
<volume>19</volume>, <fpage>653</fpage>–<lpage>656</lpage>. (<pub-id pub-id-type="doi">10.1038/nsmb.2305</pub-id>)<pub-id pub-id-type="pmid">22609859</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C213">
<label>213</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambrecht</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Brichacek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Barkauskaite</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ariza</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Hergenrother</surname><given-names>PJ</given-names></name></person-group>
<year>2015</year>
<article-title>Synthesis of dimeric ADP-ribose and its structure with human poly(ADP-ribose) glycohydrolase</article-title>. <source/>J. Am. Chem. Soc.
<volume>137</volume>, <fpage>3558</fpage>–<lpage>3564</lpage>. (<pub-id pub-id-type="doi">10.1021/ja512528p</pub-id>)<pub-id pub-id-type="pmid">25706250</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C214">
<label>214</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tucker</surname><given-names>JA</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>Structures of the human poly (ADP-ribose) glycohydrolase catalytic domain confirm catalytic mechanism and explain inhibition by ADP-HPD derivatives</article-title>. <source/>PLoS ONE
<volume>7</volume>, <fpage>e50889</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0050889</pub-id>)<pub-id pub-id-type="pmid">23251397</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C215">
<label>215</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Panzeter</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Collinge</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Althaus</surname><given-names>FR</given-names></name></person-group>
<year>1994</year>
<article-title>Endoglycosidic cleavage of branched polymers by poly(ADP-ribose) glycohydrolase</article-title>. <source/>Eur. J. Biochem.
<volume>220</volume>, <fpage>369</fpage>–<lpage>375</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1432-1033.1994.tb18633.x</pub-id>)<pub-id pub-id-type="pmid">8125093</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C216">
<label>216</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barkauskaite</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<year>2013</year>
<article-title>Visualization of poly(ADP-ribose) bound to PARG reveals inherent balance between exo- and endo-glycohydrolase activities</article-title>. <source/>Nat. Commun.
<volume>4</volume>, <fpage>2164</fpage> (<pub-id pub-id-type="doi">10.1038/ncomms3164</pub-id>)<pub-id pub-id-type="pmid">23917065</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C217">
<label>217</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrabi</surname><given-names>SA</given-names></name><etal>et al.</etal></person-group>
<year>2006</year>
<article-title>Poly(ADP-ribose) (PAR) polymer is a death signal</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>103</volume>, <fpage>18 308</fpage>–<lpage>18 313</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0606526103</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C218">
<label>218</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>DW</given-names></name><etal>et al.</etal></person-group>
<year>2004</year>
<article-title>Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>101</volume>, <fpage>17 699</fpage>–<lpage>17 704</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0406182101</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C219">
<label>219</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanai</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kanai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ohashi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Okamoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yamada</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Miwa</surname><given-names>M</given-names></name></person-group>
<year>2004</year>
<article-title>Loss of poly(ADP-ribose) glycohydrolase causes progressive neurodegeneration in <italic>Drosophila melanogaster</italic></article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>101</volume>, <fpage>82</fpage>–<lpage>86</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.2237114100</pub-id>)<pub-id pub-id-type="pmid">14676324</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C220">
<label>220</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cozzi</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2006</year>
<article-title>Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice</article-title>. <source/>J. Cereb. Blood Flow Metab.
<volume>26</volume>, <fpage>684</fpage>–<lpage>695</lpage>. (<pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600222</pub-id>)<pub-id pub-id-type="pmid">16177811</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C221">
<label>221</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuzzocrea</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<year>2007</year>
<article-title>Role of poly(ADP-ribose) glycohydrolase in the development of inflammatory bowel disease in mice</article-title>. <source/>Free Radic. Biol. Med.
<volume>42</volume>, <fpage>90</fpage>–<lpage>105</lpage>. (<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2006.09.025</pub-id>)<pub-id pub-id-type="pmid">17157196</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C222">
<label>222</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamanaka</surname><given-names>S</given-names></name></person-group>
<etal>et al.</etal>
<year>2018</year>
<article-title>Investigation of novel biomarkers for predicting the clinical course in patients with ulcerative colitis</article-title>. <source/>J. Gastroenterol. Hepatol.
<volume>33</volume>, <fpage>1975</fpage>–<lpage>1983</lpage>. (<pub-id pub-id-type="doi">10.1111/jgh.14297</pub-id>)<pub-id pub-id-type="pmid">29869393</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C223">
<label>223</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marques</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Oncogenic activity of poly (ADP-ribose) glycohydrolase</article-title>. <source/>Oncogene
<volume>38</volume>, <fpage>2177</fpage>–<lpage>2191</lpage>. (<pub-id pub-id-type="doi">10.1038/s41388-018-0568-6</pub-id>)<pub-id pub-id-type="pmid">30459355</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C224">
<label>224</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gravells</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Neale</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Nathubhai</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>James</surname><given-names>DI</given-names></name>, <name name-style="western"><surname>Bryant</surname><given-names>HE</given-names></name></person-group>
<year>2018</year>
<article-title>Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: a comparison with the PARP1/2/3 inhibitor olaparib</article-title>. <source/>DNA Repair (Amst). <volume>61</volume>, <fpage>25</fpage>–<lpage>36</lpage>. (<pub-id pub-id-type="doi">10.1016/j.dnarep.2017.11.004</pub-id>)<pub-id pub-id-type="pmid">29179156</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C225">
<label>225</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gogola</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<year>2018</year>
<article-title>Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality</article-title>. <source/>Cancer Cell
<volume>33</volume>, <fpage>1078</fpage>–<lpage>1093</lpage>. (<pub-id pub-id-type="doi">10.1016/j.ccell.2018.05.008</pub-id>)<pub-id pub-id-type="pmid">29894693</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C226">
<label>226</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tsai</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Adamik</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Stanley</surname><given-names>SJ</given-names></name></person-group>
<year>1988</year>
<article-title>Purification and characterization of ADP-ribosylarginine hydrolase from turkey erythrocytes</article-title>. <source/>Biochemistry
<volume>27</volume>, <fpage>5819</fpage>–<lpage>5823</lpage>. (<pub-id pub-id-type="doi">10.1021/bi00415a063</pub-id>)<pub-id pub-id-type="pmid">3179279</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C227">
<label>227</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>J</given-names></name></person-group>
<year>2007</year>
<article-title>Enhanced sensitivity to cholera toxin in ADP-ribosylarginine hydrolase-deficient mice</article-title>. <source/>Mol. Cell Biol.
<volume>27</volume>, <fpage>5534</fpage>–<lpage>5543</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.00302-07</pub-id>)<pub-id pub-id-type="pmid">17526733</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C228">
<label>228</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stylianou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hoffmann</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Lizak</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Glasgow</surname><given-names>CG</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>J</given-names></name></person-group>
<year>2011</year>
<article-title>ADP-ribosylarginine hydrolase regulates cell proliferation and tumorigenesis</article-title>. <source/>Cancer Res.
<volume>71</volume>, <fpage>5327</fpage>–<lpage>5335</lpage>. (<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0733</pub-id>)<pub-id pub-id-type="pmid">21697277</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C229">
<label>229</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konczalik</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>J</given-names></name></person-group>
<year>1999</year>
<article-title>Identification of critical, conserved vicinal aspartate residues in mammalian and bacterial ADP-ribosylarginine hydrolases</article-title>. <source/>J. Biol. Chem.
<volume>274</volume>, <fpage>16 736</fpage>–<lpage>16 740</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.274.24.16736</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C230">
<label>230</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller-Dieckmann</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kernstock</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lisurek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>von Kries</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Haag</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Koch-Nolte</surname><given-names>F</given-names></name></person-group>
<year>2006</year>
<article-title>The structure of human ADP-ribosylhydrolase 3 (ARH3) provides insights into the reversibility of protein ADP-ribosylation</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>103</volume>, <fpage>15 026</fpage>–<lpage>15 031</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0606762103</pub-id>)<pub-id pub-id-type="pmid">16373501</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C231">
<label>231</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abplanalp</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Proteomic analyses identify ARH3 as a serine mono-ADP-ribosylhydrolase</article-title>. <source/>Nat. Commun.
<volume>8</volume>, <fpage>2055</fpage> (<pub-id pub-id-type="doi">10.1038/s41467-017-02253-1</pub-id>)<pub-id pub-id-type="pmid">29234005</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C232">
<label>232</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pourfarjam</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ventura</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kurinov</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>IK</given-names></name></person-group>
<year>2018</year>
<article-title>Structure of human ADP-ribosyl-acceptor hydrolase 3 bound to ADP-ribose reveals a conformational switch that enables specific substrate recognition</article-title>. <source/>J. Biol. Chem.
<volume>293</volume>, <fpage>12 350</fpage>–<lpage>12 359</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.RA118.003586</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C233">
<label>233</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voorneveld</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rack</surname><given-names>JGM</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Overkleeft</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>van der Marel</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Filippov</surname><given-names>DV</given-names></name></person-group>
<year>2018</year>
<article-title>Synthetic α- and β-Ser-ADP-ribosylated peptides reveal α-Ser-ADPr as the native epimer</article-title>. <source/>Org. Lett.
<volume>20</volume>, <fpage>4140</fpage>–<lpage>4143</lpage>. (<pub-id pub-id-type="doi">10.1021/acs.orglett.8b01742</pub-id>)<pub-id pub-id-type="pmid">29947522</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C234">
<label>234</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>X</given-names></name></person-group>
<year>2018</year>
<article-title>Structure-function analyses reveal the mechanism of the ARH3-dependent hydrolysis of ADP-ribosylation</article-title>. <source/>J. Biol. Chem.
<volume>293</volume>, <fpage>14 470</fpage>–<lpage>14 480</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.RA118.004284</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C235">
<label>235</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niere</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kernstock</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Koch-Nolte</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ziegler</surname><given-names>M</given-names></name></person-group>
<year>2008</year>
<article-title>Functional localization of two poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix</article-title>. <source/>Mol. Cell Biol.
<volume>28</volume>, <fpage>814</fpage>–<lpage>824</lpage>. (<pub-id pub-id-type="doi">10.1128/MCB.01766-07</pub-id>)<pub-id pub-id-type="pmid">17991898</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C236">
<label>236</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mashimo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kato</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Moss</surname><given-names>J</given-names></name></person-group>
<year>2013</year>
<article-title>ADP-ribosyl-acceptor hydrolase 3 regulates poly (ADP-ribose) degradation and cell death during oxidative stress</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>110</volume>, <fpage>18 964</fpage>–<lpage>18 969</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.1312783110</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C237">
<label>237</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanuma</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Oyama</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yoshimori</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Abe</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Uchiumi</surname><given-names>F</given-names></name></person-group>
<year>2016</year>
<article-title>New insights into the roles of NAD+-poly(ADP-ribose) metabolism and poly(ADP-ribose) glycohydrolase</article-title>. <source/>Curr. Protein Pept. Sci.
<volume>17</volume>, <fpage>668</fpage>–<lpage>682</lpage>. (<pub-id pub-id-type="doi">10.2174/1389203717666160419150014</pub-id>)<pub-id pub-id-type="pmid">27817743</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C238">
<label>238</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottschalk</surname><given-names>AJ</given-names></name><etal>et al.</etal></person-group>
<year>2009</year>
<article-title>Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>106</volume>, <fpage>13 770</fpage>–<lpage>13 774</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.0906920106</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C239">
<label>239</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahel</surname><given-names>D</given-names></name><etal>et al.</etal></person-group>
<year>2009</year>
<article-title>Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1</article-title>. <source/>Science
<volume>325</volume>, <fpage>1240</fpage>–<lpage>1243</lpage>. (<pub-id pub-id-type="doi">10.1126/science.1177321</pub-id>)<pub-id pub-id-type="pmid">19661379</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C240">
<label>240</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottschalk</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Trivedi</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Conaway</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Conaway</surname><given-names>RC</given-names></name></person-group>
<year>2012</year>
<article-title>Activation of the SNF2 family ATPase ALC1 by poly(ADP-ribose) in a stable ALC1·PARP1·nucleosome intermediate</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>43 527</fpage>–<lpage>43 532</lpage>. (<pub-id pub-id-type="doi">10.1074/jbc.M112.401141</pub-id>)<pub-id pub-id-type="pmid">22105075</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C241">
<label>241</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sellou</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<year>2016</year>
<article-title>The poly(ADP-ribose)-dependent chromatin remodeler Alc1 induces local chromatin relaxation upon DNA damage</article-title>. <source/>Mol. Biol. Cell.
<volume>27</volume>, <fpage>3791</fpage>–<lpage>3799</lpage>. (<pub-id pub-id-type="doi">10.1091/mbc.e16-05-0269</pub-id>)<pub-id pub-id-type="pmid">27733626</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C242">
<label>242</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehmann</surname><given-names>LC</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>Mechanistic insights into autoinhibition of the oncogenic chromatin remodeler ALC1</article-title>. <source/>Mol. Cell.
<volume>68</volume>, <fpage>847</fpage>–<lpage>859</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2017.10.017</pub-id>)<pub-id pub-id-type="pmid">29220652</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C243">
<label>243</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>HR</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>A poly-ADP-ribose trigger releases the auto-inhibition of a chromatin remodeling oncogene</article-title>. <source/>Mol. Cell.
<volume>68</volume>, <fpage>860</fpage>–<lpage>871</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2017.11.019</pub-id>)<pub-id pub-id-type="pmid">29220653</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C244">
<label>244</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tsang</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>XY</given-names></name></person-group>
<year>2009</year>
<article-title>Transgenic CHD1 L expression in mouse induces spontaneous tumors</article-title>. <source/>PLoS ONE
<volume>4</volume>, <fpage>e6727</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pone.0006727</pub-id>)<pub-id pub-id-type="pmid">19701453</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C245">
<label>245</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>F</given-names></name></person-group>
<year>2013</year>
<article-title>CHD1 L: a novel oncogene</article-title>. <source/>Mol. Cancer
<volume>12</volume>, <fpage>170</fpage> (<pub-id pub-id-type="doi">10.1186/1476-4598-12-170</pub-id>)<pub-id pub-id-type="pmid">24359616</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C246">
<label>246</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brockschmidt</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<year>2012</year>
<article-title>CHD1 L: a new candidate gene for congenital anomalies of the kidneys and urinary tract (CAKUT)</article-title>. <source/>Nephrol. Dial. Transplant.
<volume>27</volume>, <fpage>2355</fpage>–<lpage>2364</lpage>. (<pub-id pub-id-type="doi">10.1093/ndt/gfr649</pub-id>)<pub-id pub-id-type="pmid">22146311</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C247">
<label>247</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michalska</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>P</given-names></name></person-group>
<year>2015</year>
<article-title>Pseudomonas Exotoxin A: optimized by evolution for effective killing</article-title>. <source/>Front. Microbiol.
<volume>6</volume>, <fpage>963</fpage> (<pub-id pub-id-type="doi">10.3389/fmicb.2015.00963</pub-id>)<pub-id pub-id-type="pmid">26441897</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C248">
<label>248</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carbonetti</surname><given-names>NH</given-names></name></person-group>
<year>2015</year>
<article-title>Contribution of pertussis toxin to the pathogenesis of pertussis disease</article-title>. <source/>Pathog. Dis.
<volume>73</volume>, <fpage>ftv073</fpage> (<pub-id pub-id-type="doi">10.1093/femspd/ftv073</pub-id>)<pub-id pub-id-type="pmid">26394801</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C249">
<label>249</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>YA</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>J</given-names></name></person-group>
<year>2017</year>
<article-title>The role of typhoid toxin in <italic>Salmonella typhi</italic> virulence</article-title>. <source/>Yale J. Biol. Med.
<volume>90</volume>, <fpage>283</fpage>–<lpage>290</lpage>.<pub-id pub-id-type="pmid">28656014</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C250">
<label>250</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stecher</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tzivelekidis</surname><given-names>T</given-names></name>, <name name-style="western"><surname>van Ham</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rohde</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hardt</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Wehland</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Aktories</surname><given-names>K</given-names></name></person-group>
<year>2009</year>
<article-title>Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria</article-title>. <source/>PLoS Pathog.
<volume>5</volume>, <fpage>e1000626</fpage> (<pub-id pub-id-type="doi">10.1371/journal.ppat.1000626</pub-id>)<pub-id pub-id-type="pmid">19834554</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C251">
<label>251</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Niu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>S</given-names></name></person-group>
<year>2016</year>
<article-title>A novel contribution of spvB to pathogenesis of <italic>Salmonella</italic> Typhimurium by inhibiting autophagy in host cells</article-title>. <source/>Oncotarget
<volume>7</volume>, <fpage>8295</fpage>–<lpage>8309</lpage>. (<pub-id pub-id-type="doi">10.18632/oncotarget.6989</pub-id>)<pub-id pub-id-type="pmid">26811498</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C252">
<label>252</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coye</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Collins</surname><given-names>CM</given-names></name></person-group>
<year>2004</year>
<article-title>Identification of SpyA, a novel ADP-ribosyltransferase of <italic>Streptococcus pyogenes</italic></article-title>. <source/>Mol. Microbiol.
<volume>54</volume>, <fpage>89</fpage>–<lpage>98</lpage>. (<pub-id pub-id-type="doi">10.1111/j.1365-2958.2004.04262.x</pub-id>)<pub-id pub-id-type="pmid">15458407</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C253">
<label>253</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherwood</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>CR</given-names></name></person-group>
<year>2016</year>
<article-title>Autophagy evasion and endoplasmic reticulum subversion: the Yin and Yang of legionella intracellular infection</article-title>. <source/>Annu. Rev. Microbiol.
<volume>70</volume>, <fpage>413</fpage>–<lpage>433</lpage>. (<pub-id pub-id-type="doi">10.1146/annurev-micro-102215-095557</pub-id>)<pub-id pub-id-type="pmid">27607556</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C254">
<label>254</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotewicz</surname><given-names>KM</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>A single legionella effector catalyzes a multistep ubiquitination pathway to rearrange tubular endoplasmic reticulum for replication</article-title>. <source/>Cell Host Microbe
<volume>21</volume>, <fpage>169</fpage>–<lpage>181</lpage>. (<pub-id pub-id-type="doi">10.1016/j.chom.2016.12.007</pub-id>)<pub-id pub-id-type="pmid">28041930</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C255">
<label>255</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhogaraju</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kalayil</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Bonn</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Colby</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Matic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Dikic</surname><given-names>I</given-names></name></person-group>
<year>2016</year>
<article-title>Phosphoribosylation of ubiquitin promotes serine ubiquitination and impairs conventional ubiquitination</article-title>. <source/>Cell.
<volume>167</volume>, <fpage>1636</fpage>–<lpage>1649</lpage>. (<pub-id pub-id-type="doi">10.1016/j.cell.2016.11.019</pub-id>)<pub-id pub-id-type="pmid">27912065</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C256">
<label>256</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>A unique deubiquitinase that deconjugates phosphoribosyl-linked protein ubiquitination</article-title>. <source/>Cell Res.
<volume>27</volume>, <fpage>865</fpage>–<lpage>881</lpage>. (<pub-id pub-id-type="doi">10.1038/cr.2017.66</pub-id>)<pub-id pub-id-type="pmid">28497808</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C257">
<label>257</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Gerdes</surname><given-names>K</given-names></name></person-group>
<year>2005</year>
<article-title>Toxin-antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes</article-title>. <source/>Nucleic Acids Res.
<volume>33</volume>, <fpage>966</fpage>–<lpage>976</lpage>. (<pub-id pub-id-type="doi">10.1093/nar/gki201</pub-id>)<pub-id pub-id-type="pmid">15718296</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C258">
<label>258</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jankevicius</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ariza</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name></person-group>
<year>2016</year>
<article-title>The toxin-antitoxin system DarTG catalyzes reversible ADP-ribosylation of DNA</article-title>. <source/>Mol. Cell.
<volume>64</volume>, <fpage>1109</fpage>–<lpage>1116</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2016.11.014</pub-id>)<pub-id pub-id-type="pmid">27939941</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C259">
<label>259</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rack</surname><given-names>JG</given-names></name><etal>et al.</etal></person-group>
<year>2015</year>
<article-title>Identification of a class of protein ADP-ribosylating sirtuins in microbial pathogens</article-title>. <source/>Mol Cell.
<volume>59</volume>, <fpage>309</fpage>–<lpage>320</lpage>. (<pub-id pub-id-type="doi">10.1016/j.molcel.2015.06.013</pub-id>)<pub-id pub-id-type="pmid">26166706</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C260">
<label>260</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Debing</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Jankevicius</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Neyts</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Coutard</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Canard</surname><given-names>B</given-names></name></person-group>
<year>2016</year>
<article-title>Viral macro domains reverse protein ADP-ribosylation</article-title>. <source/>J Virol.
<volume>90</volume>, <fpage>8478</fpage>–<lpage>8486</lpage>. (<pub-id pub-id-type="doi">10.1128/JVI.00705-16</pub-id>)<pub-id pub-id-type="pmid">27440879</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C261">
<label>261</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McPherson</surname><given-names>RL</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>ADP-ribosylhydrolase activity of Chikungunya virus macrodomain is critical for virus replication and virulence</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>114</volume>, <fpage>1666</fpage>–<lpage>1671</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.1621485114</pub-id>)<pub-id pub-id-type="pmid">28143925</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C262">
<label>262</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eckei</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>
<year>2017</year>
<article-title>The conserved macrodomains of the non-structural proteins of Chikungunya virus and other pathogenic positive strand RNA viruses function as mono-ADP-ribosylhydrolases</article-title>. <source/>Sci. Rep.
<volume>7</volume>, <fpage>41746</fpage> (<pub-id pub-id-type="doi">10.1038/srep41746</pub-id>)<pub-id pub-id-type="pmid">28150709</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C263">
<label>263</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hauer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>McPherson</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Utt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kirby</surname><given-names>IT</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Merits</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>AKL</given-names></name>, <name name-style="western"><surname>Griffin</surname><given-names>DE</given-names></name></person-group>
<year>2018</year>
<article-title>ADP-ribosyl-binding and hydrolase activities of the alphavirus nsP3 macrodomain are critical for initiation of virus replication</article-title>. <source/>Proc. Natl Acad. Sci. USA
<volume>115</volume>, <fpage>E10 457</fpage>–<lpage>E10 466</lpage>. (<pub-id pub-id-type="doi">10.1073/pnas.1812130115</pub-id>)</mixed-citation>
</ref>
<ref id="RSOB190041C264">
<label>264</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fehr</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Jankevicius</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ahel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Perlman</surname><given-names>S</given-names></name></person-group>
<year>2018</year>
<article-title>Viral macrodomains: unique mediators of viral replication and pathogenesis</article-title>. <source/>Trends Microbiol.
<volume>26</volume>, <fpage>598</fpage>–<lpage>610</lpage>. (<pub-id pub-id-type="doi">10.1016/j.tim.2017.11.011</pub-id>)<pub-id pub-id-type="pmid">29268982</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C265">
<label>265</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>AKL</given-names></name>, <name name-style="western"><surname>McPherson</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Griffin</surname><given-names>DE</given-names></name></person-group>
<year>2018</year>
<article-title>Macrodomain ADP-ribosylhydrolase and the pathogenesis of infectious diseases</article-title>. <source/>PLoS Pathog.
<volume>14</volume>, <fpage>e1006864</fpage> (<pub-id pub-id-type="doi">10.1371/journal.ppat.1006864</pub-id>)<pub-id pub-id-type="pmid">29566066</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C266">
<label>266</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atasheva</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Frolova</surname><given-names>EI</given-names></name>, <name name-style="western"><surname>Frolov</surname><given-names>I</given-names></name></person-group>
<year>2014</year>
<article-title>Interferon-stimulated poly(ADP-Ribose) polymerases are potent inhibitors of cellular translation and virus replication</article-title>. <source/>J. Virol.
<volume>88</volume>, <fpage>2116</fpage>–<lpage>2130</lpage>. (<pub-id pub-id-type="doi">10.1128/JVI.03443-13</pub-id>)<pub-id pub-id-type="pmid">24335297</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C267">
<label>267</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McInerney</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>Kedersha</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Kaufman</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Liljeström</surname><given-names>P</given-names></name></person-group>
<year>2005</year>
<article-title>Importance of eIF2alpha phosphorylation and stress granule assembly in alphavirus translation regulation</article-title>. <source/>Mol. Biol. Cell.
<volume>16</volume>, <fpage>3753</fpage>–<lpage>3763</lpage>. (<pub-id pub-id-type="doi">10.1091/mbc.e05-02-0124</pub-id>)<pub-id pub-id-type="pmid">15930128</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C268">
<label>268</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daugherty</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Kerns</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Malik</surname><given-names>HS</given-names></name></person-group>
<year>2014</year>
<article-title>Rapid evolution of PARP genes suggests a broad role for ADP-ribosylation in host-virus conflicts</article-title>. <source/>PLoS Genet.
<volume>10</volume>, <fpage>e1004403</fpage> (<pub-id pub-id-type="doi">10.1371/journal.pgen.1004403</pub-id>)<pub-id pub-id-type="pmid">24875882</pub-id></mixed-citation>
</ref>
<ref id="RSOB190041C269">
<label>269</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikiforov</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kulikova</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ziegler</surname><given-names>M</given-names></name></person-group>
<year>2015</year>
<article-title>The human NAD metabolome: functions, metabolism and compartmentalization</article-title>. <source/>Crit. Rev. Biochem. Mol. Biol.
<volume>50</volume>, <fpage>284</fpage>–<lpage>297</lpage>. (<pub-id pub-id-type="doi">10.3109/10409238.2015.1028612</pub-id>)<pub-id pub-id-type="pmid">25837229</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>